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Abstract 
Mouse bronchiolar stem cells have been identified in vivo based on functional 
characteristics including naphthalene resistance, long-term retention of labeled DNA precursors, 
and dual expression of markers for airway (CCSP) and alveolar (pro-SPC) epithelium. Further 
characterization would benefit from establishment of rigorous enrichment strategies allowing 
analysis of their behavior in vitro and following transplantation, and the establishment of a 
defining gene expression signature. We have determined that Epithelial Cell Adhesion Molecule 
(EpCAM) and Integrin α6 are expressed on the cell surface of both alveolar and bronchiolar 
epithelial cells and that low levels of Sca-1 expression characterize the bronchiolar epithelium. 
Within the Sca-1low EpCAMpos Integrinα6pos population of bronchiolar epithelial cells, 
autofluorescence (AF) levels distinguish the facultative transit-amplifying population which is 
AFhi from bronchiolar stem cells which are AFlow. Use of transgenic animal models allowing 
expansion or depletion of the stem cell compartment and use of lineage tracing strategies have 
allowed us to determine the identity of cells isolated based on their cell surface phenotype and 
autofluorescence characteristics. Injury models associated with depletion of terminally 
differentiated ciliated cells (ozone) or facultative transit amplifying population (naphthalene) 
were used to validate the functional characteristics of the two fractions of bronchiolar 
progenitors. In conclusion, we have developed and validated a fractionation approach for the 
generation of highly purified preparations of bronchiolar stem and Clara cells from the mouse 
lung. These data enable establishment of robust in vitro and transplantation assays to further 
validate the functional behavior of stem and facultative TA (Clara) cells and allows analysis of 
gene expression profile of the two populations towards a better understanding of unique 
characteristics of the bronchiolar stem cell compartment.  
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1.0  INTRODUCTION 
1.1 HETEROGENEITY OF EPITHELIAL CELLS IN THE ADULT AIRWAY 
The adult mammalian lung is a complex organ that evolved to facilitate gas transfer 
between inspired air and the blood. To accomplish this process, structural components of the 
lung are organized into a branching system of conducting airways and blood vessels that 
terminate in the gas exchange unit, the alveolus. The respiratory tract is lined by a structurally 
heterogeneous epithelium in which cell types are organized into specialized functional zones 
based upon their progenitor-progeny relationships1-3. This epithelium fulfills a range of 
secondary functions from muco-ciliary clearance4 to secretion5,6, metabolism, and the 
detoxification of either systemic or inhaled xenobiotic chemicals7-9. Epithelial cell types can be 
distinguished based upon their unique ultrastructural characteristics and gene expression profiles. 
The lining of tracheal and bronchial airways is a pseudo-stratified epithelium composed of basal 
cells, secretory cells, other less abundant nonciliated cell types such as neuroendocrine cells, 
brush cells and intermediate cells, and ciliated cells10-12. The most distal conducting airways, the 
bronchioles, are lined by a simple cuboidal epithelium consisting of Clara cells, ciliated cells and 
rare neuroendocrine cells13. Neuroendocrine cells are commonly organized into clusters, which 
are associated with nonciliated cells that lack the typical ultrastructural features of Clara cells14. 
The epithelium lining alveoli is composed of alveolar type II cells (ATII), which secrete 
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pulmonary surfactant, and alveolar type I cells (ATI), which are highly specialized epithelial 
cells with a large surface area to facilitate gas transfer3,15. 
1.2 EPITHELIAL FUNCTION 
With every inspiration the lung epithelium is exposed to micro-organisms and their 
pyrogenic by-products, viral particles, oxidative pollutants, and particulate matter.  Despite these 
persistent environmental challenges, the epithelial lining turns over at a very low rate due to 
innate hosts defense mechanisms that preserve tissue integrity16-19.  To prevent undue injury and 
an unwarranted immunological response the airway epithelium provides for physical clearance 
of inhaled stimulants through mucociliary clearance20.  In the event that mucociliary clearance is 
overwhelmed, the epithelium also plays a pivotal role in regulation of the innate inflammatory 
response.  Recent studies highlight the fact that tight regulation of the NF-kappaB signaling 
pathway in epithelial cells is required for appropriate control of the inflammatory response and 
communication with resident lung macrophages required for an effective response21-25.  
In contrast, these processes are likely compromised in the setting of chronic lung 
diseases, such as cystic fibrosis and chronic obstructive pulmonary disease, resulting in chronic 
epithelial injury, defective repair, and subsequent remodeling of the epithelial-mesenchymal 
trophic unit26.  Recently, we have demonstrated that defective epithelial repair can phenocopy 
aspects of chronic lung disease, such as bronchiolar and alveolar extracellular matrix (ECM) 
deposition and an augmented inflammatory response suggesting a role for altered progenitor cell 
behavior in disease etiology27,28.  In other organ systems, it has also been shown that 
deregulation of the stem cell compartment leads to acute and chronic diseases29,30. In the 
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hematopoietic system, for example, increased proliferation of either stem or progenitor cells can 
lead to disorders such as leukemia and lymphoma30, whereas defects in cellular differentiation 
can lead to severe immunological abnormalities31. Although evidence of a direct cause-effect 
relationship between different disease states and the status of the resident stem cell or the niche is 
currently lacking, it has been suggested that diseases such as lung cancer can arise from resident 
progenitor cells29,30. Understanding the hierarchical organization of progenitor cells within the 
lung and the relationship between these cells and changes in their behavior with lung disease 
becomes critically important. The following sections summarize what is known of progenitor 
cells within each of the three major epithelial compartments: the tracheal-bronchial epithelium, 
the intra-pulmonary airways, and the gas-exchange area.  
1.3 PROGENITOR CELLS AND LINEAGE SPECIFICATION IN THE 
DEVELOPING LUNG 
Lineage relationship amongst different cell types and progenitor-progeny relationship in 
the extra- and intra-pulmonary epithelium have been thoroughly studied in mouse models of lung 
development. One of the earliest events in lung development is formation of the two lung buds 
from the foregut endoderm. Growth of the lung primordia and subsequent branching 
morphogenesis, sacculation, and alveolarization are dependent upon appropriate interactions 
with the surrounding foregut mesoderm32. Signaling between the two compartments is mediated 
by a variety of growth factors, amongst which members of the FGF33,34, Tgf-β/BMP35, and 
Wnt36,37 families of paracrine regulatory factors play central roles. The tracheal epithelium arises 
from different foregut endoderm progenitors located anterior to the initial lung buds forming 
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within the foregut endoderm. Initially the trachea and the esophagus form a common tubular 
structure that is subsequently partitioned into two separate tubular organs32. Despite the distinct 
origins of extrapulmonary versus intrapulmonary airways the finding that distal lung 
mesenchyme can redirect primitive tracheal epithelium to a distal fate suggests that early 
endodermal progenitor cells are multipotent and that their fate is tightly regulated by paracrine 
interactions with surrounding mesenchyme38,39. Thus, epithelial cells of the conducting and 
alveolar airways, including basal, ciliated, secretory, neuroendocrine, and alveolar type I and II, 
arise from common endodermal progenitors. However, a growing body of evidence suggests that 
once lung endoderm has been specified in the embryonic foregut, the ensuing process of lung 
development yields distinct lineages that are maintained independently of one another in the late 
embryonic and postnatal periods. This developmental process has been reviewed extensively 
elsewhere32. 
1.4 ADULT STEM CELLS AND TISSUE MAINTENANCE BY A STEM CELL 
HIERARCHY 
The term adult tissue stem cell was coined to describe cells with the ability to proliferate 
and generate differentiated progeny within a tissue, yet retain the capacity for long-term self-
renewal.  Unlike embryonic stem cells, a pluripotent cell type that can be maintained in culture 
by providing medium additives but lack a stable in vivo counterpart, adult tissue stem cells 
generally have more restricted differentiation potential and can be maintained for prolonged 
periods in vivo40,41. Cells with these characteristics were first described in the hematopoietic 
system. The capacity of hematopoietic stem cells to generate all specialized cell types of the 
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hematopoietic lineage and undergo long-term self-renewal were only validated through use of in 
vivo transplantation assays42,43. Similar cells have since been described in other organs including 
the intestine44-46, nervous system47, epidermis48,49, and epithelial of the cornea50, mammary 
gland51-53, lung17,18,54,55, liver56,57, pancreas58, and prostate59.  However, tissue-specific 
differences in the kinetics of cell replacement coupled with anatomic constraints and differences 
in cellular complexity have made identification and classification of stem cells difficult in many 
tissues. Accordingly, a range of other properties have been used to define the stem cell 
compartment within a tissue and the mechanisms contributing to their regulation. Such 
mechanisms may be less uniformly applicable and in some cases can only be applied to stem 
cells of a single tissue type. Relevant properties of stem cells and their more specialized 
derivatives are discussed below in the context of understanding stem cell behavior within the 
lung and other tissues, and assays commonly used for their identification and characterization.   
The classical view of a stem cell hierarchy is that rare stem cells are believed to 
proliferate infrequently and divide asymmetrically.  Asymmetric division yields one daughter 
that is identical to the parent cell and another that has more limited capacity for self renewal. The 
latter has the ability to generate large numbers of differentiating progeny and it was therefore 
termed the transit-amplifying (TA) cell41,60,61. Despite this, not all putative tissue stem cells have 
been shown to undergo asymmetric division. Moreover, among those tissue stem cells that have 
been shown to undergo asymmetric cell divisions, regulatory mechanisms have been defined for 
just a few62,63. The best described mechanism defines self-renewal of drosophila germline stem 
cells, for which asymmetric divisions are tightly regulated through adhesion complexes formed 
between stem cells and somatic cells that form the stem cell niche64. Even though there is 
support for the concept that asymmetric cell division may in some cases control long-term 
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maintenance of tissue stem cells, far less is known of mechanisms that govern the life span and 
behavior of TA cells. Tissue-specific differences are observed in the lifespan of TA cells which 
has potential to impact the activity of tissue stem cells. The life span of TA cells is dictated by 
two variables: the probability of self-renewal versus differentiation and their proliferative 
frequency. The impact that the probability of TA cell differentiation has on tissue homeostasis is 
evident in a comparison of TA cells of the intestinal epithelium and the interfolicular epidermis. 
Both of these tissues harbor TA pools that proliferate frequently for normal tissue maintenance 
but differ in their longevity. TA cells of the intestinal epithelium exhibit a relatively high 
probability of generating post-mitotic progeny leading to their rapid depletion and continuous 
requirement for stem cell proliferation to maintain regenerative capacity. In contrast, TA cells of 
the interfolicular epidermis have a relatively low probability of generating post-mitotic progeny 
leading to their long-term maintenance and infrequent activation of stem cells65,66. These 
examples serve to highlight how changes in the probability of TA self renewal versus 
differentiation have potential to dramatically impact the requirement for stem cell activation in 
tissue maintenance and help to explain tissue-specific differences in stem cell behavior. 
 
1.5 APPROACHES TO CHARACTERIZE AND HIERARCHICALLY ORGANIZE 
PROGENITOR CELLS 
A number of approaches have been developed to identify progenitor cells, understand 
their behavior in vivo, and to distinguish tissue stem cells from TA cells within a stem cell 
hierarchy. The more commonly used are discussed briefly below: 
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1.5.1 Lineage Analysis 
Progenitor-progeny relationships can be defined in vivo through use of labeling methods 
to tag cells and determine their fate. Three principal approaches have been used. The most 
straight forward approach is to label the nascent DNA of S-phase cells through incorporation of 
nucleotide analogs. Commonly used nucleotide analogues include tritiated thymidine (TdR) or 
bromodeoxyuridine (BrdU), although other halogenated thymidine analogues have also been 
used such as chlorodeoxyuridine (CldU) and iododeoxyuridine (IdU)1,3,67-69. Delivery of these 
labeled DNA precursors into the systemic circulation results in their delivery to proliferating 
cells and incorporation into DNA during S-phase. Incorporation into nuclear DNA is typically 
assessed by either autoradiographic or immunohistochemical detection. When coupled with 
either ultrastructural analysis by transmission electron microscopy or immunophenotypic 
analysis at the light microscopic level, it is possible to determine the phenotype of proliferating 
cells and with an appropriate chase period in the absence of label, the fate of their progeny. 
Caveats with this approach are that experiments involving pulse-chase strategies do not allow for 
the retrospective identification of the parental cell that initially incorporated labeled DNA 
precursors, and that continuing proliferation of cells leads to label dilution which renders this 
method useless for lineage analysis.  
An alternative method that allows analysis of lineage relationships is that of lineage 
labeling using recombinant retroviral vectors70 71. Mixed populations of retroviral vectors 
carrying different reporter genes allow for the analysis of clonality and lineage relationships. A 
caveat with this approach is the inability to retrospectively define the phenotype of the founding 
cell for a population of tagged cells that are identified after a defined “chase” period. Many of 
these technical hurdles have been overcome through use of lineage tracing methods involving 
 8 
Cre/LoxP technologies41,72. Cre recombinase is a bacteriophage enzyme that catalyzes 
homologous recombination between adjacent LoxP sequences. Any DNA sequence that is 
engineered to include two adjacent copies of the LoxP sequence can serve as a substrate for Cre. 
Recombination catalyzed by Cre can lead to either deletion or reversal of the intervening 
sequence depending upon whether the LoxP elements are in the same or opposing relative 
orientation, respectively. A prerequisite for lineage analysis using the Cre/LoxP system is that 
progenitor cell-specific genes have been identified and their promoters characterized allowing 
the generation of transgenic mice capable of directing cell type-specific expression of Cre. Mice 
carrying the Cre-expressing transgene are crossed with a reporter line in which a LoxP-flanked 
transcriptional terminator sequence is present between an upstream ubiquitous promoter and a 
downstream reporter gene. In this case, Cre-mediated recombination activates the expression of 
the down-stream reporter, thus introducing a lineage tag within the cell that can be traced among 
daughter cells. When this strategy is coupled with use of ligand-regulated forms of Cre such as 
CreER, lineage tags can be introduced into defined cell types in a temporally controlled fashion 
72,73.  
1.5.2 In vivo  Label-Retention  
The concept that tissue stem cells proliferate infrequently compared to their transit-
amplifying progeny formed the basis for assays to define these populations based upon this 
distinguishing characteristic. Infrequently proliferating cells have been identified in organs with 
high cellular turnover by labeling nuclear DNA with nucleotide analogues as discussed in detail 
above, followed by a chase period that dilutes the label within frequently cycling cells74,75. This 
assay has been used to define “label-retaining” cells (LRC).  One pre-requisite of such 
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experiments is that the stem cell actively proliferates at the time of the pulse labeling.   However, 
recent evidence in the intestinal stem cell compartment challenges the label-retaining dogma and 
shows that there is a population of non-label retaining stem cells at the bottom of the crypt, 
distinct from the classical LRC found 4 cells upstream from the bottom of the crypt (+4). 
Lineage tracing analysis demonstrates that these stem cells have the ability to generate the entire 
epithelium of the crypt and the villus, including the +4 epithelial cells45. Another limitation of 
this approach is its reliance on the difference in proliferation rate between the highly proliferative 
TA compartment and the relative quiescence of the stem cell. Thus, in organs with very low 
cellular turn-over such as the lung, pancreas, and liver, where both compartments proliferate 
infrequently in steady state, various injury models have been used to reveal the difference in 
proliferative potential of stem vs TA cell populations 17,18,55,58,76,77. In these organs, chemical 
injury and/or tissue resection was used to reveal a population of label retaining cells with stem 
cell properties.  
1.5.3 In vitro and transplantation assays 
In vitro assays are dependent upon the existence of a set of positive and negative 
selection markers that allow prospective isolation of stem cell enriched populations. Once such 
enrichment is possible, the self-renewal and differentiating properties of these cells can be 
studied in clonogenic, serial-passage, and limited dilutions analysis assays78,79.  However, in 
vitro experiments have the caveat of being dependent upon subjective medium components and 
are very susceptible to false interpretation due to inadequate culturing conditions that can bias 
progenitor cell renewal or differentiation independently of whether these cells function as tissue 
stem cells in vivo. Transplantation assays are rooted in the hematopoietic stem cell field where 
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functional validation of stem cell behavior can be verified through analysis of the capacity for 
long-term reconstitution of the entire hematopoietic system from one single cell42,43,78. This type 
of approach has been effectively employed in both the mammary gland and prostate to 
demonstrate that single cells isolated based on specific cell surface markers can reconstitute the 
entire gland when transplanted in immuno-compromised hosts51,52,59.  
1.6 PROGENITOR CELLS OF TRACHEOBRONCHIAL AIRWAYS 
Analysis of clonogenic, differentiation, and proliferative potential of progenitor cells in 
the tracheobronchial epithelium have benefited from the use of in vitro80 and transplantation81 
assays as well as in vivo models of epithelial injury and repair82.  Transplantation studies in the 
trachea have been quite successful due to the relative ease of cell isolation, identification of cell 
surface markers for fractionation, and surgical transplantation compared to their more distal 
counterparts.  Early work demonstrated that progenitor cells could be isolated from the tracheal 
epithelium, fractionated according to their ability to interact with the lectin Griffonia 
simplicifolia I (GSI)-B4, transplanted into denuded rat tracheas, and differentiate appropriately to 
restore the cellular diversity of the tracheal epithelium81,83.  From this study more sophisticated 
approaches have been utilized to more thoroughly define the progenitor capacity of tracheal 
epithelial cells.  In a classical study, Engelhardt and colleagues isolated human bronchial 
epithelial cells, transduced these cells with retroviral constructs expressing a reporter gene for 
use in lineage tracing, and transplanted the cells into a denuded rat trachea.  By analyzing the cell 
types represented in each clone, this study demonstrated that a single progenitor cell can give rise 
to all the cells of the airway surface epithelium in addition to the cells of the submucosal 
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glands84.  These results suggest that a progenitor cell with more stem-like properties exists within 
the tracheobronchial compartment.  In addition to these observations, this study is one of only a 
few to investigate human airway progenitor cell behavior.  Unfortunately, the stochastic nature 
of retroviral transduction precluded a determination of the molecular or cellular identity of the 
initiating clonogenic cell.   Each of these studies relied upon isolating cells from intact tissues, 
which could bias the experimental outcome based upon cellular viability during the isolation 
procedure.  Therefore, a series of in vivo studies were initiated to better characterize the stem cell 
hierarchy in the tracheal epithelium.   
Borthwick and colleagues repeatedly injured the tracheal epithelium through exposure to 
SO2 or polydocanol and simultaneously treated with BrdU to label proliferating cells.  To 
determine if a stem cell niche exists in the tracheal epithelium, label retaining cells in the 
repairing epithelium were quantified after various chase periods.  These data demonstrated that 
label retaining cells existed in the upper and lower trachea in the sub-mucosal glands and at the 
junction of the inter-cartilaginous rings, respectively.  This study also demonstrated that keratin 5 
(Krt5) positive subsets of basal cells could be identified in tissue based upon activity of the β-
galactosidase (β-GAL) reporter under control of the human Krt5 promoter16.  Krt5 expressing 
cells were never immunolocalized with the label retaining cells. However, their localization to 
submucosal gland ducts and junctions of inter-cartilaginous rings was suggestive evidence that 
the label retaining cell may be Krt5 positive.  This study provided in vivo evidence that a stem 
cell niche may exist in the tracheal epithelium.  The precise molecular and cellular identity of 
these label retaining cells remains unknown and recent studies have questioned label retention as 
a relevant assay for defining stem cell potential45.  Collectively, these studies demonstrated that 
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epithelial progenitors exist in the tracheal epithelium, with a subpopulation of these cells sharing 
characteristics of resident adult tissue stem cells.   
 To determine the cellular identity and molecular profile of the tracheal epithelial 
stem cell a combination of in vivo lineage tracing and in vitro assays were utilized.  These studies 
have demonstrated that subsets of tracheal and bronchial basal epithelial cells can be 
characterized by their multipotent differentiation potential.  In 2004, both Schoch and colleagues 
as well as Hong and colleagues reported that the expression of keratins 5 and 14, respectively, 
demarcate cells with multipotent differentiation potential85-87.  Using a ubiquitously expressing 
β-GAL transgenic mouse, Shoch and colleagues demonstrated that the mouse tracheal epithelium 
contains a population of cells capable of clonal expansion and multipotent differentiation when 
cultured in vitro, confirming the previous observations made by Engelhardt and colleagues in 
human xenograft transplantation.  Based upon the previous observation that Krt5 expression 
defines a subset of basal epithelial cells in the tracheal epithelium, a transgenic reporter mouse 
expressing EGFP under the control of the human Krt5 promoter was used to fractionate tracheal 
basal cells.  Fluorescent activated cell sorting and in vitro culturing indicated that EGFP positive 
cells display multipotent differentiation capacity and increased clonogenic potential relative to 
EGFP negative epithelial cells85.  In contrast, Hong and colleagues used an in vivo lineage 
tracing strategy.  A bitransgenic mouse line expressing the fused CRE-ERt under control of the 
Krt14 promoter crossed with the ROSA26-flox-stop recombination substrate was utilized to 
establish differentiation and clonogenic potential.  In this study, it was demonstrated that 
following naphthalene ablation of secretory cells, Krt14 expressing basal cells display either 
multipotent or unipotent differentiation capacity87,86.  The relationship between the Krt5 and 
Krt14 expressing basal cells is currently unknown.   Further fractionation of basal cells in 
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conjunction with in vitro and transplantation assays will be required before this relationship can 
be effectively studied. However, data to date suggest that basal cells are a heterogeneous 
population that includes a subset with greater clonogenic and differentiation potential suggesting 
that this subpopulation of basal cells may be the equivalent of a local tissue stem cell.  
If cell based therapeutic approaches are to be implemented, faithful cell surface markers 
that allow for fractionation of progenitor cells must be identified.  Several methods have been 
utilized to fractionate tracheal and bronchial epithelial cells.  Previous work in the hematopoietic 
system fractionated stem cells on the basis of the phenotypic ability to rapidly efflux Hoechst 
dye, termed side population (SP) cells88.  As such, several studies in the tracheal and bronchial 
epithelium have adopted this approach.  Unfortunately, in mouse this method has been highly 
irreproducible indicating that the SP cell may be either epithelial or mesenchymally derived89,90.  
Despite this, a recent study used this approach to fractionate human SP tracheal and bronchial 
epithelial cells and analyze their differential potential in vitro.   The results of this study indicate 
that human SP cells are capable of differentiating into epithelial cells.  However, whether the SP 
enriches for cells with clonogenic or differentiation potential remains to be determined91.  
Regardless, it is evident that adopting cell surface markers or phenotypic profiles used to 
fractionate stem cells in other compartments does not guarantee enrichment of airway 
progenitors.  Recent work has also demonstrated that human airway epithelial progenitors can be 
isolated, grown in three dimensional culture, efficiently transduced, and are capable of 
restoration of the airway epithelium in denuded tracheas92.  In addition, these progenitor cells can 
be fractionated based upon the expression of aquaporin-3 to enrich for progenitor cell capacity93.  
Despite the current inability to reproducibly purify subpopulations of progenitor cells, a seminal 
study recently demonstrated that cell based therapeutic intervention in lung disease is now a 
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reality.  In a proof of principle study, Macchiarini and colleagues conducted the world’s first 
human main bronchus transplant using a donor denuded trachea seeded with recipient airway 
epithelial cells.  The patient had presented with a stenosis of the left main bronchus and severely 
attenuated forced vital capacity (FVC) and FEV1 (forced expiratory volume in 1 second) levels 
due to tuberculosis infection. Four months following transplantation, the epithelium was 
completely restored, FVC and FEV1 levels returned to normal, and no signs of allograft rejection 
were apparent94.  Although the study cannot rule out invasion of the recipient’s own epithelial 
cells into the transplanted trachea, it yields great promise for the future of lung regenerative 
medicine.  Collectively, these data indicate that despite the low rate of epithelial turnover in the 
tracheal and bronchial epithelium, this compartment maintains a sub-population of epithelial 
cells with incredible differentiation and clonogenic potential.  Future studies are needed to 
adequately harness the potential of these cells in the treatment lung disease.  
1.7 PROGENITOR CELLS OF BRONCHIOLAR AIRWAYS 
 The identity of bronchiolar progenitor cells and their differentiation potential was 
initially studied using TdR labeling methods to mark proliferative cells in the normal and 
repairing epithelium. Evans and colleagues, using Ozone and NO2 injury models to selectively 
injure ciliated cells in rat airways demonstrated that epithelial renewal is accomplished through a 
wave of proliferation. Pulse-chase experiments involving systemically delivered [3H]-thymidine 
(TdR) were used to demonstrate that nonciliated bronchiolar (Clara) cells represented the only 
proliferative cell type that responded to ciliated cell injury and that daughter cells gave rise to 
either mature Clara or ciliated cells2. Furthermore, the authors very thoroughly describe the 
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morphological changes that secretory cells go through in order to enter the cell cycle and 
replenish the pool of terminally differentiated ciliated cells. Thus, the name Type A Clara cell 
was used in reference to Clara cells that have lost both secretory granules and smooth 
endoplasmic reticulum, ultrastructural changes that were accompanied by cell cycle progression 
through S-phase1. These findings indicated that secretory cells are multifunctional, fulfilling 
roles in secretion and metabolism in the resting state, yet proliferating in response to injury to 
effect renewal of the epithelium. This duality of function for airway progenitor cells is in contrast 
to the obligate progenitor function observed among transit-amplifying cells in classical stem cell 
hierarchies, thus the term facultative transit-amplifying (TA) cells. 
The existence of bronchiolar stem cells and their contribution to repair has been 
suggested from analysis of airway injury models involving selective ablation of mature Clara 
cells. Clara cells of mammalian airways constitutively express phase I metabolizing enzymes 
such as cytochrome P450 that render them susceptible to injury by their enzymatic substrates. 
Clara cells of the mouse airway express cytochrome P450 isoenzymes 2B2 and 2F2 that 
metabolize naphthalene to toxic metabolites leading to selective cell death95.  This model of 
naphthalene-induced airway injury has been used to investigate mechanisms of repair following 
depletion of this abundant pool of facultative TA cells 18,55,96-99.   Clara cell ablation is followed 
by a proliferative response, the magnitude, spatial context, and kinetics of which are dictated by 
the extent of injury and airway location, leading to renewal of the epithelium97,100. Repair of the 
Clara cell depleted bronchiolar epithelium is accomplished through activation of putative tissue 
stem cells that localize to two discrete microenvironments including bronchoalveolar duct 
junctions (BADJ) and neuroepithelial bodies (NEB)17,97.  Using this injury-repair model, Hong et 
al and later Giangreco et al identified naphthalene-resistant CCSP-expressing cells that 
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incorporate labeled DNA precursors into nuclear DNA during the early repair response and show 
a long-term label-retaining phenotype indicative of an infrequently cycling tissue stem cell18,55. 
The term variant CCSP-expressing (vCE) cell was used to differentiate this population of 
naphthalene-resistant cells from naphthalene-sensitive Clara cells. A direct role for vCE cells in 
repair of naphthalene-injured airways was further supported through use of a transgenic mouse 
model allowing ablation of the entire CCSP expressing population18,96. In this model, conditional 
ablation of all CCSP-expressing progenitor cells, both naphthalene-sensitive Clara cells and the 
putative bronchiolar stem cell, was accompanied by complete abrogation of bronchiolar 
repair18,96. More recently, naphthalene-resistant vCE cells residing at the BADJ were found to 
exhibit the unique molecular property of expressing the alveolar type II epithelial cell marker 
gene pro-surfactant protein-C99. Cells with this CCSP/Pro-SPC expressing phenotype have been 
proposed as a multipotent bronchioalveolar stem cell based upon in vitro data suggesting that 
they can generate cells expressing either airway or alveolar marker genes when cultured in 
vitro99. It has not been determined whether resident bronchiolar stem cells, either those defined 
based upon their resistance to naphthalene or other putative stem cells, have the capacity to 
generate and renew alveolar epithelium in addition to that of the bronchiole.  
Localization of naphthalene-resistant vCE cells to defined microenvironments within 
bronchioles suggests that these regions are analogous to stem cell niches described in other 
organs 48,101. However, what actually constitutes the stem cell niche and what local factors 
regulate maintenance and activation of the stem cell population remain unknown. 
Neuroepithelial body-associated CCSP-expressing cells have the distinguishing properties of 
both naphthalene-resistance and unique electrophysiological properties suggesting that local 
microenvironmental factors regulate cellular behavior102. Properties of NEB-associated CCSP-
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expressing cells that may confer resistance to naphthalene-induced airway injury include reduced 
expression of phase I xenobiotic metabolizing enzymes such as CYP2F2 17. Collectively, these 
data argue that extrinsic factors controlled by the local microenvironment impact the behavior of 
bronchiolar progenitor cells for maintenance of the stem cell phenotype, and that this phenotype 
confers intrinsic resistance to environmental agents such as naphthalene.    
Insight into molecular pathways that regulate the behavior of bronchiolar progenitor cells 
come from studies involving use of mouse models carrying genetic perturbations of specific 
signaling pathways. Experiments using a Cre recombinase-activated form of the K-ras gene were 
the first to suggest that activation of this transducer of pro-mitotic signaling pathways had the 
potential to impact the behavior of bronchiolar progenitor cells103. Epithelial hyperplasia coupled 
with an increase in the abundance of CCSP/SP-C dual positive cells suggested that active K-ras 
signaling led to expansion of cells with some characteristics of the bronchiolar stem cell prior to 
formation of adenomas and peripheral lung adenocarcinomas. In addition to providing insight 
into possible mechanisms regulating stem cell pool size, this study also provided support for the 
idea that tissue stem cells may be the cell of origin for lung cancer. In contrast, activation of 
Wnt/β-catenin signaling, a pathway directly linked to epithelial carcinogenesis and stem cell 
maintenance in the gut, led to expansion of bronchiolar stem cells without evidence of 
hyperplastic/neoplastic transformation104. In this study, potentiation of β-catenin signaling at the 
time of bronchiolar epithelial cell specification that occurs during the late embryonic period of 
lung development resulted in the expansion of a cell population that is naphthalene resistant, 
highly proliferative in response to airway injury, and co-expresses CCSP and SP-C. The ability 
of Wnt/β-catenin pathway to expand the pool of airway stem cells through altering the 
maturation of developmental progenitor cells suggested that down-regulation of this pathway in 
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the developing airway is necessary for establishment of the normal balance between stem cells 
and specialized cell types of the bronchiolar epithelium105,106. Changes in the abundance of the 
putative bronchiolar stem cell population defined by co-expression of CCSP and SP-C were also 
seen in mice homozygous for a null allele of the Gata-6 gene107. Gata-6 deficient mice displayed 
enhanced Wnt/β-catenin signaling in the developing lung suggesting that β-catenin can function 
as a common transducer for multiple signaling pathways that have potential to regulate airway 
progenitor cell behavior. However, the finding that specific deletion of β-catenin within the 
airway epithelium late in development did not impact epithelial maturation or the capacity to 
undergo repair following injury suggests that β-catenin is not necessary for the bronchiolar stem 
cell activation or maintenance106. These findings suggest that multiple signaling pathways have 
the potential to impact stem cell pool size and differentiation potential. Other potential molecular 
regulators of the stem cell compartment studied to date include p38α MAP kinase, PI-3 kinase, 
Bmi-1, and PTEN108-111. However, even though disregulation of these pathways impacts the 
behavior of stem/progenitor cells in vivo, the pathway/s involved in physiological regulation of 
the stem cell within the niche have not yet been defined.  
Further efforts to characterize cellular components of the bronchiolar stem cell hierarchy 
and their regulation have involved isolation and fractionation of airway progenitor cells. Caveats 
with this approach are that dissociation of lung tissue eliminates spatial cues that aid in the 
definitive identification of the bronchiolar stem cell defined by naphthalene resistance, and the 
common problem that gene expression analysis suffers from potential artifacts introduced during 
the isolation procedure. However, some of these difficulties have been overcome through use of 
genetically modified mouse models to introduce lineage tags and regulate progenitor cell pool 
size.  Methods used for preparation of lung cells either enrich for certain epithelial cell types 
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through use of defined protease cocktails coupled with application to lung tissue in a manner that 
restricts enzymatic activity to a localized compartment 8,112, or have used methods for isolation 
of all lung cells113.   
Enrichment of different members of the bronchiolar stem cell hierarchy is highly 
dependent upon the existence of specific positive and negative selection strategies that exploit 
either biochemical or molecular characteristics to effect fractionation of a mixed population of 
cells89,99,113-115.  The use of known markers for tissue stem cells, such as stem cell antigen-1 (Sca-
1), has been used most frequently89,99. A strategy based upon positive selection for Sca-1 and 
CD34, and negative selection for CD45 and CD31, was used to enrich cells that were 
immunoreactive for both CCSP and SP-C from crude preparations of cells isolated using a 
method for enrichment of alveolar epithelial cells96. When placed in culture these cells have the 
ability to express aquaporin 5, CCSP and SP-C, markers for alveolar and airway epithelium, 
leading to the proposal that these cells have potential for either alveolar or airway differentiation 
and hence may represent a bronchioalveolar stem cell (BASC).  
A significant hurdle to progress is the lack of novel marker genes that define the stem cell 
and more abundant facultative TA cell compartments. Recent studies in the gut have provided 
novel molecular markers that distinguish subsets of intestinal progenitor cells with stem cell 
activity45. However, validation of these marker genes is complex and requires rigorous in vivo 
lineage tracing. A number of strategies have been used to broaden the repertoire of molecular 
markers for analysis of epithelial cell differentiation in the developing and adult lung. Microarray 
analysis of lung tissue during naphthalene injury and repair led to the identification of novel 
genes that define the naphthalene-sensitive Clara cell population.  Many of these genes including 
Claudin10, FMO3, PON1, AO3, are expressed in a developmental sequence within maturing 
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airway secretory cells116.  However, these strategies have not revealed genes that specifically 
define the bronchiolar stem cell due to the rarity of this cell population in the lung.  
 
1.8 PROGENITOR CELLS OF THE ALVEOLAR COMPARTMENT 
The gas exchange area of the lung is lined by alveolar epithelial cells. There are two 
types of alveolar epithelial cells with different functional and morphological features. Alveolar 
type I (ATI) cells are thin flat cells that line the alveolus and juxtapose the endothelial cells, 
together forming the gas exchange area. They are the predominant epithelial cell type in the 
alveolar compartment and can be identified based on T1α (RTI40), caveolin 1 and aquaporin 5 
expression15. Alveolar type II (ATII) cells are larger, cuboidal cells whose main function is 
surfactant production and they can differentiate into ATI cells3. Alveolar type II cells can be 
distinguished at the ultrastructural level by the presence of lamellar bodies and microvilli117. 
Although in the adult mouse ATII produce surfactant proteins A, B and C (SP-A, SP-B and SP-
C), SP-C expression is considered to be a unique marker for mature ATII cells118,119. Despite 
this, SP-C is one of the earliest genes expressed in the lung epithelium15. In the developing 
mouse lung, cells expressing SP-C appear at the tips of epithelial branches as early as E 10.5 
indicating that expression of this gene product has potential to mark immature lung progenitor 
cells in addition to mature ATII cells32. These cells are highly proliferative in the developing 
lung and give rise to both mature epithelial cell types of the alveolar compartment. However, the 
alveolar epithelium turns over very slowly in uninjured mature alveolus120. 
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A number of injury models have been used as tools to investigate mechanisms of alveolar 
repair. Commonly used agents to elicit alveolar injury include hyperoxia5,121 and NO23, resulting 
in predominantly ATI and endothelial cell injury. Repair mechanisms have been investigated 
largely through use of strategies to label proliferative cells such as the use of labeled DNA 
precursors such as TdR or BrdU3.  In such models, ATII cells represent the only labeled 
epithelial cell population immediately after in vivo delivery of labeled nucleotide analogues3. 
However, studies using a labeling period followed by a chase in the absence of label have shown 
that proliferating ATII cells can either self-renew or give rise to ATI cells, thus demonstrating 
the progenitor-progeny relationship between these two cell types3. Very similar findings have 
been observed following isolation and culture of ATII cells, in which their capacity to proliferate 
and generate ATI cells has been clearly demonstrated118,122. Further in vitro studies have also 
raised the possibility that ATI cells may, under some conditions, exhibit the capacity proliferate 
and contribute to epithelial renewal123. However, the question from these experiments is whether 
cells cultured in vitro that exhibit some features of ATI cells, either morphological and/or 
molecular, are truly representative of their in vivo counterpart. 
Studies similar to those performed in conducting airways identifying putative local tissue 
stem cells have not been performed in the alveolar compartment. Despite this, it is clear that not 
all ATII cells proliferate in response to alveolar damage and there is evidence of heterogeneity 
among ATII cell population 121,124,125. It has been proposed that a bronchioalveolar stem cell 
exists that at least in vitro has the capacity for long-term maintenance and the generation of 
progeny that express some genes indicative of both bronchiolar and alveolar differentiation99. 
However, a cell type capable of contributing to both bronchiolar and alveolar epithelial lineages 
has not been demonstrated in vivo. Furthermore, evidence arguing that bronchiolar and alveolar 
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lineages are maintained as distinct regenerative compartments in the adult lung has been 
generated using in vivo lineage tracing studies115. These in vivo observations in animal models 
support the finding in human patients suffering from distal lung diseases with either alveolar wall 
destruction or fibrosis, that the alveolar compartment has a limited ability to repair and restore 
normal function.  
1.9 RATIONALE  
The lung epithelium turns over slowly in normal conditions but has significant 
regenerative capacity that can be activated following injury1,2. This regenerative capacity is 
critical for homeostasis due to continual exposure of the lung to injurious stimuli by either 
systemic or inhalation routes. Chronic injury leads to the establishment of disease states such as 
idiopathic pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, and lung 
cancer126. Treatments with curative rather than palliative intent are currently unavailable for most 
of these diseases and our understanding of their pathogenesis is limited.  In this regard, 
deciphering the molecular phenotype and mechanisms governing behavior of different 
components of the bronchiolar stem cell hierarchy becomes crucial in designing effective 
therapeutic interventions. 
The main goal of the work presented here is to develop and validate methods that allow 
for prospective isolation and molecular and functional characterization of airway stem and 
progenitor cells. Transgenic animal models associated with either expansion or depletion of the 
bronchiolar stem cell compartment together with lineage tracing approaches enabled us to 
identify and fractionate lung epithelial progenitor and stem cells. Injury and repair models 
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confirmed their hierarchical organization according to their in vivo proliferative and 
differentiation potential. 
 24 
2.0  MATERIAL AND METHODS 
2.1 ANIMAL HUSBANDRY  
 Mice were bred and maintained in AAALAC approved facilities at the University of 
Pittsburgh and at Duke University. Animals used for experiments were maintained in pathogen 
free conditions with unrestricted access to food and water on a 12h light/dark cycle. All 
experiments were performed according to IACUC approved protocols on mice between 2-6 
months of age.  
2.2 TRANSGENIC ANIMAL MODELS AND GENOTYPING 
 Genotyping was performed by PCR amplification of genomic DNA isolated from the 
mouse tail by previously published method. Primer pairs and PCR conditions have been 
previously described104,127,128 
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Table 1. Transgenic animal models  
Genotype Acronym Use of transgene 
CCSP Herpes simplex virus 
thymidine kinase 
CCTK Ablation of the stem and facultative 
TA population following ganciclovir 
treatment 
CCSPcre Catnb floxE3/flox E3 ∆E3 Amplification of the stem cell 
population 
CCSPcreRosa26FloxSTOP EYFP CCSPcre LSL EYFP Lineage tracing of the bronchiolar 
epithelium (green bronchiolar 
epithelium) 
SP-Ccre 
Rosa26TdTomatoFlox/FloxEGFP 
SP-Ccre 
TdTomato/EGFP 
Lineage tracing of the intrapulmonary 
lung epithelium (green alveolar and 
bronchiolar epithelium) 
Rosa26TdTomatoFlox/FloxEGFP TdTomato/EGFP 
 
Ubiquitous TdTomato mice 
FoxJ1 GFP FoxJ1 GFP 
 
GFP expression in ciliated cells 
SP-C GFP SP-C GFP GFP expression in alveolar type II 
cells and bronchiolar stem cells 
 
 
2.3 GANCICLOVIR TREATMENT OF CCTK ANIMALS 
Ganciclovir (GCV) was administered using a miniosmotic pump (Alzet, CA) loaded with 
50mg/ml solution (w/v) in PBS for delivery at a rate of 8µl/hour over a 24 hour period18. 
Miniosmotic pumps were primed in sterile saline (0.9% NaCl) for 2hours prior to subcutaneous 
implantation. Mice were anaesthetized with Ketamine (100mg/kg body weight) and Xylazine 
(10mg/kg of body weight). Pumps were placed subcutaneously through a 1.5cm incision in the 
back skin. Mice were recovered for 6 days in normal cage environment.   
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2.4 BROMO-DEOXY-URIDINE ADMINISTRATION 
Bromo-deoxy-Uridine (BrdU) (Sigma, St.Luis, MO) was resuspended in pirogen free 0.9% NaCl 
solution (B.Brown Medical Inc., Irvine, CA) at a concentration of 6mg/ml and administered i.p. 
at 50mg/kg body weight at 12 hours intervals.  
2.5 OZONE INJURY 
         For ozone exposures, 14 weeks old C57B6 males were exposed to 1.5ppm ozone for 12 
hours and control mice were exposed to filter air for the same period of time. Mice were 
removed from their housing cages, and placed separately into individual  
stainless-steel wire cage units; these units were placed into 55-liter stainless-steel  
Hinners-style exposure chamber. The chamber was equipped with a high efficiency filtered  
air supply, such that chamber air (50-60% relative humidity air and a temperature of 20-22 C) 
was renewed at the rate of approximately 20 changes/h. Ozone was generated by passing 100%  
oxygen gas through an ultraviolet light source that was positioned upstream of the  
air supply to the chamber. Ozone is metered into the inlet air supply and the ozone  
concentration was monitored continuously within the chamber with an ozone ultraviolet  
light photometer (Dasibi model 1003AH; Dasibi Environmental Corporation, Glendale,  
CA). The photometer was calibrated regularly against a standard ozone source129-131.  
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2.6 NAPHTHALENE INJURY 
Naphthalene exposures were performed using 10 weeks old male C57B6 mice. Naphthalene 
(Fisher Scientific) was dissolved in corn oil (Mazolla) at a concentration of 25mg/ml and it was 
administered i.p. at a dose of 250mg/ kg body weight (see also Appendix A3)18,55,104. 
2.7 CELL ISOLATION 
 Airway epithelial cells were isolated based on a previously published method8,104. Mice 
were anesthetized and exsanguinated, the thoracic cavity was opened, the lungs were exposed 
and the trachea cannulated. Lungs were perfused with 10ml PBS and lavaged 4 times with 1ml 
PBS 0.2µM EGTA. One ml of 4U/ml Elastase solution (Worthington) was instilled in the 
airways and incubated for 5 minutes at 37oC followed by three 0.5ml instillations for 5 minutes 
each. Lung lobes were removed following Elastase digestion, minced, and incubated with DNase 
I solution (0.5mg/ml) for 10 minutes at 37oC. Cells were resuspended in 30mls ice cold 
HBSS(Gibco), pipetted up and down to release the epithelial cells and passed through a 100µm 
or a 70μm cell strainer. Five milliliters of FBS were added slowly at the bottom of each tube and 
the samples were spun by centrifugation at 500g for 8 minutes. Red blood cells (RBC) were 
lysed in RBC lysing buffer (eBioscience) on ice for 1 minute.  Following RBC lysis, cells were 
resuspended in 25mls of HBSS 10mMHEPES, 2% fetal bovine serum and centrifuged at 500g 
for 8 minutes. Cells were resuspended in 500μl of HBSS 10mMHEPES, 2% fetal bovine serum 
and live cells were counted based on Trypan blue exclusion. For a detailed protocol, see 
Appendix A1.  
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2.8 FLOW CYTOMETRY 
 Isolated cells were resuspended at 1 x 106 cells in 100µl HBSS, 10mM HEPES, 2% fetal 
bovine serum (staining solution), and incubated with the indicated antibodies for 30 minutes at 
4oC in the dark. For antibodies description see table 2. Cells were washed with 1ml staining 
solution, resuspended in 300µl staining solution and analyzed using either a FACSVantage (BD 
Biosciences, San Jose, CA), a FACS Canto(BD Biosciences, San Jose, CA) or FACS CantoII 
(BD Biosciences, San Jose, CA). Propidium iodide (PI) (2μl/100μl cell suspension) or 7-Amino-
Actinomycin D (7-AAD) (5μl/100μl cell suspension) was used for dead cell discrimination. 
Sorting experiments were performed using a FACS Vantage (BD Biosciences, San Jose, CA) or 
a FACS Aria (BD Biosciences, San Jose, CA) sorter. Data was analyzed using FlowJo 7.2.4 
software (Tree Star, Inc). 
For CCSP intracellular staining, cells were permeabilized using a 0.1% (v/v) Tween20 
solution for 30min on ice, followed by incubation with FITC directly conjugated rabbit anti-
CCSP antibody (1:10000 in house). To directly conjugate the CCSP antibody we used Zenon 
Direct Conjugation kit (Invitrogen, CA) according to the manufacturer instructions. 
BrdU staining was performed using the BrdU FITC kit from BD Biosciences (San Jose, 
CA) according to the manufacturer instructions. For details on the staining procedure, necessary 
controls and data analysis see Appendix A2.  
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2.9 IMMUNOFLUORESCENCE  
Cells were cytospun onto glass slides and fixed in 10% NBF for 30 minutes. Cells were 
permeabilized using 0.5% TritonX100 (v/v) in PBS for 30 minutes, blocked in 5% BSA (w/v) in 
PBS for 30 minutes and incubated with the primary antibody for one hour at room temperature: 
polyclonal rabbit anti-CCSP (in house,1:10000) and polyclonal goat anti-CCSP (in house, 
1:10000) and rabbit anti-Pro-SPC (1:2500, kind gift from Y.P. Di, U. Pittsburgh) (see table2). A 
fluorescently labeled secondary antibody was added for one hour and slides were mounted using 
Fluoromount G (SouthernBiotech) with 4, 6, diamidino-2-phenylindole (DAPI , 2µg/ml) as a 
nuclear counterstain. Alternatively, paraffin embedded lung tissue was sectioned (5 µm 
thickness), deparaffinized in Xylene and rehydrated in decreasing concentrations of ethanol in 
PBS. Tissue used for frozen sections was cryprotected in 30% Sucrose in PBS for 3 to 4 hours 
with continuous shaking, followed by overnight degassing at room temperature. Tissue was then 
embedded in OCT, frozen at -80oC, and sectioned at 5µm thickness. Cryo-sections were 
dehydrated in 100% ethanol and rehydrated in decreasing concentrations of ethanol in PBS. 
When necessary, antigen retrieval was performed using the microwave method followed by 
incubation in 0.05% Trypsin/EDTA tissue culture grade (Cellgro, Mediatech Inc, Manassas, VA) 
for 10 minutes at 37oC. Slides were blocked in 5% BSA (w/v) in PBS and the primary antibody 
was added for 3 hours at room temperature (see Table 2). Slides were incubated for 1 hour at 
room temperature with a fluorescent secondary antibody and mounted in DAPI containing 
Fluoromount-G (2µg/ml). Fluorescent images were acquired using an Olympus Provis AX70 
microscope equipped with a Spot RT digital camera. The same acquisition and analysis 
parameters were used for all samples in each experiment.  Images were processed and analyzed 
using AdobePhotoshop (Adobe Systems Inc., San Jose, CA).   
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Table 2. Primary antibodies used for flow cytometry and tissue histology 
Antigen Host  Titer Source 
CCSP Goat polyclonal 1:10000 (IF), 1:20000 
(FC) 
In house 
CCSP Rabbit polyclonal 1:10000 (IF) In house 
proSP-C Rabbit polyclonal 1:3000 (IF) Kind gift from P.Y. 
Di 
FoxJ1 Mouse IgG1 1:1500 (IF) Kind gift from S. 
Brody 
BrdU Rat IgG2A 1:500 (IF) Accurate Chemical 
BrdU Mouse 1:100 (FC) BD Biosciences 
GFP Rabbit polyclonal 1:1000 (IF) Abcam 
Sca-1 Rat IgG2A Clone D7 2:100(FC-
eBiosciences) and 
1:200 (FC-Biolegend) 
eBioscience and 
Biolegend 
Sca-1 Rat IgG2A Clone 13-
161.7 
2:100 (FC) Biolegend  
EpCAM (FITC, PE-
Cy7) 
Rat IgG2A Clone 
G8.8 
1:200 (FC), 1:100 (IF) Biolegend 
Integrin alpha6 
(CD49f PE and Alexa 
Fluor 647) 
Rat IgG2A Clone 
GoH3 
5:400 (FC ) , 1:200 
(IF) 
eBioscience and 
Biolegend 
CD45 (PE-Cy7, 
Biotinylated) 
Rat IgG2B Clone 30-
F11 
1:200 (FC-BD 
Biosciences) and 
3:200 (FC-
eBioscience) 
BD Biosciencies, 
eBioscience 
CD31 (PE-Cy7, 
Biotinylated) 
Rat IgG2A, Clone 390 2:100 (FC) eBioscience and 
Biolegend 
CD34 (Alexa Fluor 
647, Biotinylated) 
Rat IgG2A, Clone 
RAM34 
13:200 (FC) eBioscience 
2.10 RNA ISOLATION AND REAL TIME PCR  
Total RNA was isolated from single cell suspension using Promega SV Total RNA 
(Promega, Madison, WI) isolation kit, following manufacturer’s instructions. RNA was reverse-
transcribed using Superscript First Strand Synthesis Kit (Invitrogen, Carlsbad, CA) according to 
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the manufacturer’s protocol and relative mRNA abundance of genes of interest was assessed 
using TaqMan FAM labeled probes (Applied Biosystems, Foster City, CA) and AB TaqMan 
7000 Real Time System (Applied Biosystems, Foster City, CA). 
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3.0  SCA-1 AND CD34 EXPRESSION AND AUTOFLUORESCENCE 
CHARACTERISTICS OF EPITHELIAL CELLS OF THE RESPIRATORY 
EPITHELIUM 
3.1 INTRODUCTION 
.  In previous work by us and others, bronchiolar stem cells were characterized as 
naphthalene resistant, label retaining, CCSP expressing cells that are spatially localized to either 
broncho-alveolar duct junctions or branch point-associated neuroepithelial bodies 18,55,97,99. Based 
upon these criteria bronchiolar stem cells have either been termed variant Clara cells (Clara(v)) 
according to their unique functional properties but similarity with Clara cells in their expression 
of CCSP18,55, or bronchioalveolar stem cells (BASC’s) due to their co-expression of the airway 
marker CCSP and alveolar marker Pro-SPC , their Sca-1pos CD34pos cell surface phenotype, and 
their ability to express marker genes for both airway and alveolar epithelium in vitro99.  
In the present study, we used transgenic animal models allowing ablation18,96, lineage 
tagging104,132, and expansion104 of the stem cell population to verify the cell surface phenotype of 
bronchiolar stem cells. We found that Sca-1 does not distinguish bronchiolar stem cells from the 
more abundant pool of facultative TA (Clara) cells and that neither population express cell 
surface CD34. We determine that bronchiolar stem and facultative TA (Clara) cells share the 
common property of low cell surface expression of Sca-1 that distinguished them from Sca-1high 
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lung cells, and can be distinguished from each other based upon their autofluorescence (AF) 
characteristics. Accordingly, bronchiolar stem cells can be defined based upon their CD45neg 
CD31neg CD34neg Sca-1low AFlow phenotype.  
3.2 RESULTS: 
3.2.1 Sca-1 and CD34 expression in single cell preparations of lung cells 
It has previously been proposed that the bronchiolar stem cells can be distinguished from 
other lung epithelial cell types by virtue of their cell surface expression of Sca-1 and CD34. In 
their analysis Kim and colleagues prepared lung epithelial cells using methods that enrich for 
alveolar epithelial cells99. We sought to determine whether cell surface expression of Sca-1 and 
CD34 allowed the prospective fractionation of bronchiolar stem cells from the abundant pool of 
facultative TA (Clara) cells. To address this question we interrogated expression of Sca-1 and 
CD34 on the surface of lung epithelial cells isolated using established methods that enrich 
populations of airway epithelial cells8,104. Single cell preparations were obtained by Elastase 
digestion of normal mouse lung and further enriched based upon negative selection for cell 
surface CD45 and CD31, and positive selection for viable cells based upon exclusion of PI or 
7AAD ( Figure 1). The profile of the CD45neg CD31neg live population prior to staining for Sca-1 
and CD34 (Figure 2A, upper left panel) revealed two distinct populations based on their 
autofluorescence in the AF647 and PE channels. Staining of this population for Sca-1 (Figure 
2A, upper right panel) revealed two distinct Sca-1 positive populations: a less abundant Sca-1high 
(R4 gate=5.33% of CD45neg CD31neg live population) and a more abundant Sca-1low population 
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(R3 gate =18.3% of CD45neg CD31neg live population). The Sca-1high population was comprised 
exclusively of low autofluorescent (AFlow) cells, while the Sca-1 low population was comprised 
of both AFhigh and AFlow cells. Staining the CD45neg CD31neg PIneg population for CD34 (Figure 
2A, lower left panel) revealed a CD34pos fraction (R1 gate = 12.11%) derived exclusively from 
the AFlow population. Staining for the combination of all markers and analysis of the CD45neg 
CD31neg live population revealed that Sca-1pos CD34pos cells (R2 gate) accounted for 4.62% of 
the population (Figure 2A, lower right panel, and Figure 2A). We next determined the spatial 
localization of Sca-1 positive cells by immunofluorescent staining of lung tissue sections (Figure 
2C). Sca-1 immunoreactivity was evident in cells outside the airway epithelium with apparently 
high expression levels detected within endothelial cells lining blood vessels. Consistent with this 
pattern of immunolocalization was the observation that more than 95% of the CD31 (PECAM) 
positive cells from lung cell preparations were Sca-1 positive (data not shown and Kotton et 
al.,133). Within the airway epithelium, Sca-1 immunoreactivity was only detected on the 
basolateral membrane of epithelial cells residing within proximal intrapulmonary airways. 
Epithelial cells of the distal conducting airway showed no evidence of Sca-1 immunoreactivity 
above baseline levels in this analysis. Taken together, these data demonstrate that Sca-1 is a 
broadly expressed marker in the lung, and that levels of Sca-1 immunoreactivity vary 
significantly between cell types. The high proportion of CD45neg CD31neg Sca-1pos CD34pos cells 
in isolated cells raised the question of whether Sca-1 or CD34 are appropriate and/or specific cell 
surface markers for rare bronchiolar stem cells.  
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               Figure 1. Exclusion of CD45pos CD31pos and dead cells. 
Flow cytometry analysis of isolated lung cells showing the side scatter forward scatter profile (A), exclusion of PIpos 
dead cells (B), and CD45pos CD31pos cells (C). 
 
 
 
 
 
 
 
 36 
 
 37 
              Figure 2.  Sca-1 and CD34 expression in the lung 
(A) Flow cytometry analysis of Sca-1 and CD34 expression on the cell surface of CD45neg CD31neg live single cell 
preparations from mouse lung (See Figure 1 for parameters used for initial selection of cells to be interrogated). 
Panels represent unstained control (upper left), Sca-1 stained sample (upper right), CD34 stained sample (lower left) 
and Sca-1 and CD34 stained sample. Gates identify populations as follows: R1 – CD34 positive population, R2 – 
Sca-1 and CD34 dual positive population, R3 – Sca-1low population, R4 – Sca-1high population. Unstained sample: 
R1=0.27%, R2=0.00, R3+R4=0.17%; Sca-1 stained sample: R1=0.14% R2=0.01% R3=18.3 R4=5.33%, CD34 
stained sample: R1=12.11% R2=0.00% R3=0.38% R4=0.00% Sca-1 CD34 dual stained sample: R1=2.75% 
R26.07% R3=11.94% R4=0.30%. (B) Quantitative representation of data in (A). Data represent averages with 
standard error of the mean for 7 samples from 3 separate experiments. Data represent % of live CD45neg CD31neg 
population: R1=3.1% R2=4.62% R3=14.34% R4=0.46%. (C) Immunofluorescence staining of lung sections 
demonstrating the spatial localization of Sca-1 positive cells in the lung. Top row: Sca-1 (red) immunolocalization. 
Bottom row: overlay of Sca-1 staining with the nonciliated airway epithelial cell-specific marker CCSP (green). 
BADJ: broncho-alveolar duct junction. Images were taken at 200x magnification. 
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3.2.2 Sca-1 expression in Clara cell depleted lungs.  
 To further examine the population of lung epithelial cells that are positive for cell 
surface Sca-1 immunoreactivity we used a transgenic approach to ablate Clara cell secretory 
protein (CCSP)-expressing cells of the airway epithelium. In this model, expression of Herpes 
Simplex virus thymidine kinase under the mouse CCSP promoter allows ablation of the entire 
CCSP expressing population following GCV treatment. We have previously demonstrated that 
GCV exposure of CCSP-HSVtk (CCTK) transgenic mice results in ablation of both the abundant 
facultative TA (Clara) cell population and rare bronchiolar stem cells18. At day 6 post GCV 
treatment CCSP-expressing cells were significantly depleted (Figure 3). Isolated lung cells 
recovered from either untreated or GCV treated mice were interrogated by flow cytometry. After 
exclusion of dead and CD45pos CD31pos cells, Sca-1 and CD34 expression was analyzed and 
compared between treated and untreated animals (Figure 4A). In the absence of CCSP-
expressing cells the size of the CD45neg CD31neg Sca-1pos CD34pos population did not change 
while the number of CD45neg CD31neg Sca-1pos CD34neg population increased, suggesting that 
other cells in the lung have the ability to express and upregulate Sca-1 in response to this mode 
of injury (Figure 4A and C).  
 Ganciclovir treatment resulted in loss of the AFhigh population (unstained sample 
in Figure 4A and Figure 4B), suggesting that some or all CCSP-expressing cells have the 
property of high autofluorescence. To further explore this possibility, isolated cells from wild 
type animals were analyzed by flow cytometry for intracellular CCSP expression and their 
autofluorescence characteristics determined (Figure 4D). Overlay of the autofluorescence 
profiles of the CCSP-immunoreactive population and the no primary antibody control sample 
demonstrates that the majority of the CCSP-expressing cells belong to the AFhigh population. 
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Importantly, a less abundant fraction of CCSP-expressing cells were localized to the AFlow 
population, suggesting that there are distinct sub-populations of CCSP-expressing cells in the 
airway epithelium. In conclusion, these data confirm that Sca-1 expression is not unique to the 
airway epithelium and that the AFhigh population contains a sub-population of secretory cells. By 
inference, these data suggest that an abundant CCSP-expressing cell population with the 
characteristics of high autofluorescence accounts for a significant fraction of Sca-1low CD34neg 
cells identified within the CD45neg CD31neg live fraction of lung epithelial cells. 
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              Figure 3. Assessment of the level of injury 6 days post GCV treatment 
Real time PCR quantification of relative mRNA levels of airway specific genes CCSP and Cyp2f2 and the alveolar 
type II cell marker SP-C.  
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                       Figure 4.Sca-1 and CD34 expression following depletion of CCSP-expressing cells 
Flow cytometry analysis of Sca-1 and CD34 expression on the surface of CD45neg CD31neg live cells isolated from 
untreated mice (top row) or CCSP-HSVtk transgenic mice recovered for 6 days post ganciclovir (GCV) treatment 
(bottom row). Left column represents unstained samples and right column represents Sca-1 CD34 dual stained 
sample. (B) Overlay of the autofluorescence (AF) profile (unstained sample) of CD45neg CD31neg live cells isolated 
from untreated mice (purple contour) or CCSP-HSVtk transgenic mice recovered for 6 days post ganciclovir (GCV) 
treatment (black contour) demonstrating the disappearance of the AFhigh population following ablation of CCSP-
expressing airway epithelial cells. (C) Quantification of data in (A). The percentages of cells in each of the three 
gates (Sca-1pos CD34pos, Sca-1neg CD34pos and Sca-1pos CD34neg) were compared between untreated (dark grey bars) 
and GCV treated (light grey bars) samples. (D) Intracellular staining for CCSP of cells isolated from a wild type 
animal showing the presence of CCSP-immunoreactive cells in the AFhigh population.  The panels represent unstained 
sample (top left), no primary control (top right), CCSP stained sample (bottom left) and overlay of the 
autofluorescence profiles of the CCSP positive (red contour) and no primary control (black contour plot) samples 
(bottom right).  
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3.2.3 The cell-surface phenotype of lineage tagged airway epithelial cells.  
To clarify the cellular origins of different populations of isolated lung cells, a lineage 
tracing mouse model was employed. In these mice, tagging of secretory cells and their progeny 
was achieved by CCSP-Cre mediated recombination of a floxed stop sequence knocked into the 
Rosa 26 locus (ROSA-LSL-eYFP). Excision of the stop sequence allowed expression of eYFP 
protein132. Analysis of eYPF expression within CCSP-Cre/ROSA-LSL-eYPF demonstrated a 
pattern of recombination that was airway-specific and accounted for approximately 90% of 
bronchiolar epithelial cells as has been reported previously for other Cre substrates (Figure 5 and 
reference104). Lineage tagged bronchiolar cells included both CCSP-expressing cells and ciliated 
cells, consistent with the known lineage relationship between these cell populations1. Flow 
cytometry analysis of isolated lung cells from CCSP-Cre ROSA-LSL-eYFP mice and analysis 
for autofluorescent characteristics identified two distinct populations of eYFPpos cells: one 
showing high autofluorescence and one showing low autofluorescence (Figure 6A).  
To address the lineage relationship between the two populations of CD45neg CD31neg Sca-
1pos cells, we analyzed eYFP expression in the Sca-1low and Sca-1high populations (Figure 6B). 
The Sca-1low population (12.74% of the CD45negCD31neg live population) had 23.6% eYFPpos 
cells while the Sca-1high population (1.85% of the CD45negCD31neg live population) had very few 
eYFPpos cells (6.97%). These data demonstrate that Sca-1low but not Sca-1high cells contain 
CCSP-expressing cells and their derivatives. Analysis of CD45neg CD31neg CD34pos cells 
indicated that the CD34pos population did not belong to the bronchiolar lineage, as the vast 
majority of CD34pos cells were eYFP negative. Moreover, in the Sca-1 CD34 stained sample, the 
CD45neg CD31neg Sca-1pos CD34pos population lacked eYFPpos cells, demonstrating that cell 
surface staining for both Sca-1 and CD34 identified a population of cells independent of the 
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bronchiolar lineage (Figure 6B). Together these data demonstrate that expression of Sca-1 and 
CD34 is not a characteristic of airway epithelial cells, but that low levels of cell surface Sca-1 
defines two populations of bronchiolar epithelial cells that can be segregated according to their 
autofluorescence characteristics.     
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Figure 5. Recombination frequency in the airways of CCSPcre Rosa26-LSL-EYFP 
Representative immunofluorescence images of lung sections from CCSP-Cre Rosa26EYFP mice stained for CCSP 
(red) and eYFP (green). Right column shows images of distal airway epithelium and the left column shows images 
of the proximal airway epithelium (200 x magnifications). 
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Figure 6. Lineage tracing to identify cell types contributing to cell fractions defined by cell surface 
Sca-1 and CD34 
(A) Flow cytometry analysis of the lineage tag (eYFP) in cells isolated from CCSP-Cre Rosa26-LSL-eYFP lungs. 
Left panel shows eYFP expression in the live CD45 CD31 negative population. Two distinct eYFPpos populations 
were identified (eYFPpos AFhigh and eYFPpos AFlow). Overlay of the autofluorescence profiles of the two populations 
(eYFPpos AFhigh - red contour and eYFPpos AFlow - green contour) demonstrates that they correspond to the high and 
low autofluorescence populations, respectively (right panel). (B) Sca-1 and CD34 expression among isolated, 
lineage tagged, airway epithelial cells. Left column: Sca-1 and CD34 staining; right column: eYFP analysis of cells 
in the indicated gates. Unstained: eYFP expression in an unstained sample; Sca-1 low vs high: eYFP expression in 
the Sca-1low population (R3, red contour) and the Sca-1high population (R4, green contour) in a Sca-1 stained sample; 
CD34 positive: eYFP expression in the CD34 positive population (R2, red contour) of a CD34 stained sample; Sca-
1/CD34 dual positive: eYFP expression in the Sca-1pos CD34pos population (R5, red contour). In all experiments 
dead and CD45pos CD31pos cells have been excluded from the analysis.  
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3.2.4 Bronchiolar stem cells are defined by their CD45neg CD31neg CD34neg Sca-1low cell 
surface phenotype and low autofluorescence.   
 The absence of definitive assays to identify bronchiolar stem cells in isolated cell 
preparations required the use of genetic models of stem cell expansion to verify their molecular 
phenotype. We have previously shown that stabilization of β-catenin in the airway epithelium 
late in lung development resulted in the appearance of supernumerary bronchiolar stem cells 
based upon the resistance of these cells to naphthalene, their proliferative potential and 
expression of putative stem cell markers104. Histologically, the lungs of ∆E3 mice  (mice 
expressing stabilized β-catenin) have significantly more CCSP/Pro-SPC dual positive cells 
compared to wild type lungs (reference104 and Figure 7A). Single cell suspensions were prepared 
from lungs of wild type and ∆E3 mice, and the properties of bronchiolar epithelial cells 
interrogated by flow cytometry. No differences were observed between cell preparations isolated 
from wild type and ∆E3 mice in the abundance of Sca -1pos CD34pos cells within the CD45neg 
CD31neg live fraction (Figure 7B and C). These data are consistent with our earlier demonstration 
that cells of the bronchiolar lineage exhibit a Sca-1pos CD34neg phenotype (Figures 6B). To 
confirm that airway epithelial cells are not found in the Sca-1pos CD34pos fraction but mostly in 
the Sca-1pos CD34neg fraction, cells were sorted according to their Sca-1 and CD34 expression 
profiles into four fractions: CD45neg CD31neg Sca-1pos CD34pos, CD45neg CD31neg Sca-1pos 
CD34neg, CD45neg CD31neg Sca-1neg CD34pos and CD45neg CD31neg Sca-1neg CD34neg. 
Immunofluorescence analysis of epithelial markers CCSP and Pro-SPC revealed that the 
CD45neg CD31neg Sca-1pos CD34neg fraction had 57.74% CCSP Pro-SPC dual positive cells in 
wild type and 51.18% in ∆E3 fraction (Figure 8B). Morphologically, CD45neg CD31neg Sca-1pos 
CD34neg cells isolated from ∆E3 mice were smaller and had a lower cytoplasmic/nucleus ratio 
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compared to wild-type cells (Figure 8A). This finding was consistent with our previous 
demonstration that potentiation of β-catenin in bronchiolar cells of ∆E3 mice results in cells that 
lack cytoplasmic organelles typical of the facultative TA (Clara) cells104. We noted that in both 
genotypes the majority of CCSP positive cells were also Pro-SPC positive. This unexpected 
finding was in contrast to the molecular phenotype of cells characterized in situ, in which only 
∆E3 mice show expansion of the bronchiolar pool of CCSP/ Pro-SPC dual positive cells. The 
CD45neg CD31neg Sca-1pos CD34pos fraction contained a population of large cells that were 
positive only for Pro-SPC, suggesting that mature alveolar type II cells localized to this fraction. 
In conclusion, we show that Sca-1 and CD34 dual-expression failed to capture the increase in 
stem cell pool size in ∆E3 animals. This finding is consistent with our earlier analysis in which 
cells of the bronchiolar lineage were localized exclusively to the CD34neg fraction. 
 Since autofluorescence characteristics of bronchiolar cells represented another 
parameter allowing their segregation we sought to test whether inclusion of this parameter 
provided a tool for identification of stem cells. We speculated that autofluorescence might relate 
to the high metabolic activity of facultative TA (Clara) cells and as such, represents a physical 
property that distinguishes Clara cells from bronchiolar stem cells. Comparison of the 
autofluorescence characteristics of the CD45neg CD31neg live cells isolated from wild type and 
∆E3 mice revealed a dramatic decrease in the size of the autofluorescent population recovered 
from ∆E3 mice (Figure 7B unstained sample and Figure 9A). To determine if the combination of 
positive and negative markers that we determined so far is instrumental in revealing the increase 
in stem cell numbers in the ∆E3 mice, we further interrogated cell surface expression of CD34 
and Sca-1 as a function of autofluorescence levels within the CD45neg CD31neg live population 
(Figure 9). Comparison of the Sca-1pos population between wild-type and ∆E3 cells 
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demonstrated a slight increase in Sca-1pos cells in the ∆E3 genotype (Figure 9B vs 9E, 17.94% vs 
22.94% respectively). Exclusion of CD34pos cells and AFhigh cells allowed us to compare the 
CD45neg CD31neg CD34neg Sca-1low AFlow population between wild-type and ∆E3 genotypes 
(Figure 9C and F). The ∆E3 CD45 neg CD31neg CD34neg Sca-1low AFlow population was 
dramatically expanded over its wild type counterpart (Figure 9G, 18.04% vs 9.2% of live 
CD45neg CD31neg respectively, p=0.0002), reflecting the stem cell expansion associated with 
stabilization of β-catenin. Since our previous analysis of this fraction of cells indicated that both 
epithelial and non-epithelial cell types are represented, the approximately two-fold increase in 
cells localizing to this population underrepresented the actual change in stem cell pool size that 
accompanies potentiation of β-catenin in ∆E3 mice. These data strongly suggest that bronchiolar 
stem cells can be distinguished from the more abundant pool of facultative TA (Clara) cells 
based upon their low autofluorescent characteristics, and provide a strategy for their prospective 
fractionation and analysis.  
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            Figure 7. The cell surface phenotype of wild type and ∆E3 cells 
Immunofluorescence analysis of Pro-SPC (red) and CCSP (green) in lung section from wild type (left column) and 
CCSP-Cre, CatnnbfloxE3/floxE3 (∆E3) animals (right column). The top row shows Pro-SPC staining and the bottom row 
represents merged images of Pro-SPC and CCSP staining (200x magnification). Insets represent higher 
magnification images of the outlined areas. (B) Sca-1 and CD34 expression on the surface of cells isolated from 
wild type (top row) and ∆E3 animals (bottom row). In left to right order, each column represents unstained, Sca -1 
stained, CD34 stained and Sca-1 and CD34 dual stained samples respectively. Dead and CD45pos CD31pos cells have 
been excluded from this analysis. (C) Quantification of data in (B), comparing the percentages of cells in each 
population of Sca-1/CD34 dual stained samples from wild type (grey bars) and ∆E3 (white bars) mice.  
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Figure 8.CCSP/ Pro-SPC staining of cells sorted according to their Sca-1/CD34 cell surface 
expression. 
Cells in each of the Sca-1neg CD34pos, Sca-1neg CD34neg, Sca-1pos CD34neg and Sca-1pos CD34pos populations were 
sorted. Cytospins from each fraction were stained with CCSP (green) and Pro-SPC. (A) 400x images of CCSP/ Pro-
SPC stained cytospins demonstrating the presence of CCSP Pro-SPC dual positive cells in the Sca-1pos CD34neg 
fraction. (B) Cells in each fraction were counted and classified either as CCSP positive (upper left graph), Pro-SPC 
positive (upper right) or CCSP and Pro-SPC dual-positive (lower graph). The graphs represent data from 3 wild type 
animals (black bars) and 3 ∆E3 animals (hatched bars).  
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Figure 9. Expansion of the stem cell population in the ∆E3 mice results in an increase in the number 
of AFlow, Sca-1pos cells 
Cells were isolated from either wild type (A-C) or ∆E3 (D-F) mice, depleted of dead and CD45pos CD31pos cells, and 
Sca-1 expression analyzed in the AFlow population (green shaded gate). (A) and (D) The AFhigh (red) and AFlow 
(green) populations of cells from wild-type and ∆E3 mice were identified in the FITC / APC-Cy7 channels. (B) and 
(E) Expression of Sca-1 in the AFlow population of Sca-1 stained samples was analyzed and compared between 
genotypes.(C) and (F) Sca-1pos CD34neg populations in the AFlow population of Sca-1 CD34 stained samples was 
compared between genotypes. (G) Quantification of data in (C) and (F). The number of cells in the Sca-1pos CD34neg 
population of 6 wild-type and 6 ∆E3 animals from three independent experiments, shows the enrichment in Sca -1 
positive cells in the ∆E3 phenotype (p<0.0005). 
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3.3 DISCUSSION 
We show that Sca-1, a previously described cell surface marker for the bronchioalveolar 
stem cell99, is a common cell surface marker for a broad population of bronchiolar epithelial 
progenitor cells that include the abundant pool of facultative TA (Clara) cells and naphthalene-
resistant bronchiolar stem cells. We found that bronchiolar progenitor cells could be 
distinguished from many other epithelial and mesenchymal cell types based upon their Sca-1low 
phenotype. Bronchiolar cells could be further subdivided based upon their autofluorescence (AF) 
characteristics; facultative TA (Clara) cells displaying an AFhigh phenotype whereas bronchiolar 
stem cells exhibited an AFlow phenotype. This fractionation approach was validated using 
strategies involving targeted cell ablation, lineage tagging, and stem cell expansion, and provides 
a robust set of criteria for further investigation of isolated bronchiolar stem cells at molecular and 
functional levels.  
Our demonstration that bronchiolar stem cells can be enriched for within dissociated 
mouse lung preparations based upon their CD45neg CD31neg CD34neg Sca-llow AFlow phenotype 
differs from the previously described characteristics of isolated bronchioalveolar stem cells 
detailed by Kim and colleagues99. Differences between our findings are that in our study Sca-1 
did not distinguish between subsets of CCSP-expressing cells (facultative TA versus stem cells), 
that the epithelial Sca-1low fraction was a relatively abundant component of the total cell 
preparation,  and that epithelial cells defined by a CCSP-Cre activated lineage tag were negative 
for CD34. The basis for these differences may be related to methods used for cell isolation 
and/or antibodies used to define cell surface phenotype. Lung cell preparations used for analysis 
by Kim and colleagues were generated using dispase/collagenase digestion coupled with 
methods optimized for the isolation of alveolar type II pneumocytes 99. In contrast, lung cell 
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preparations used herein were generated through use of Elastase and methods optimized for 
inclusion of a broad population of epithelial cells from the conducting airway and alveolus8. 
Importantly, bronchiolar stem cells from both bronchoalveolar duct junction and neuroepithelial 
body microenvironments in addition to the abundant pool of facultative TA (Clara) cells should 
be represented among dissociated cell preparations used in this study. This would not be the case 
using preparations that largely exclude epithelial cells from conducting airways. Furthermore, 
explanations for the differences in cell surface CD34 reactivity observed herein and that of Kim 
and colleagues remain to be determined. The possibility that absence of CD34 reactivity among 
lung epithelial cell types in this study results from conditions used for proteolytic dissociation of 
cells would seem unlikely as this antigen is preserved on the surface of other non-epithelial cell 
types.  
Stem cells are commonly thought to exhibit less differentiated character than their transit-
amplifying progeny. Whereas this distinction is difficult to make for rapidly renewing tissues 
such as the epithelium of the small intestine, for which both populations appear to proliferate 
frequently and lack characteristics of specialized epithelial cells45, it is more apparent within the 
progenitor cell hierarchy of the bronchiolar epithelium. We demonstrate that Clara cells, an 
abundant facultative TA cell type of bronchiolar airways, exhibits the distinguishing 
characteristic of high autofluorescence. This characteristic of Clara cells is supported through: 1) 
loss of the AFhigh fraction of lung cells following ablation of CCSP-expressing cells (including 
Clara and stem cells) in GCV treated of CCSP-HSVtk transgenic mice, and 2) loss of AFhigh cells 
following airway potentiation of β-catenin signaling. Autofluorescence is a well known 
characteristic of the airway epithelium134. In human patients autofluorescence bronchoscopy is 
used as a screening tool for lung cancer134-136. Malignant cells in lung cancer patient, which are 
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poorly differentiated in character, are detected as low level autofluorescence fields within a high 
autofluorescent background of healthy epithelial cells134-136. Collectively these data argue that 
stem cells can be distinguished from their more differentiated derivatives based upon 
autofluorescence characteristics and that this property is common between airway stem cells and 
tumor cells.  
Bronchiolar epithelial cells observed in airways of mice following constitutive 
potentiation of β-catenin signaling lack differentiated features (cytoplasmic organelles and 
differentiation markers) typical of facultative TA (Clara) cells, are resistant to naphthalene 
injury, and show a CCSP/Pro-SPC dual expressing phenotype, all characteristics of the 
bronchiolar stem cell99,104. However, even though co-expression of CCSP and Pro-SPC has the 
potential to distinguish bronchiolar stem cells from more abundant facultative TA (Clara) cells in 
vivo, our data suggest that this may not be the case following enzymatic dissociation and sorting 
of lung cells. We find that all CCSP-immunoreactive cells present within the Sca-1low fraction 
(both AFhigh and AFlow populations) show a Pro-SPC-immunoreactive phenotype. These data 
suggest that Pro-SPC immunoreactivity does not distinguish between facultative TA (Clara) cells 
and bronchiolar stem cells following enzymatic dissociation of lung tissue and subsequent 
fractionation of isolated cells. This is consistent with our observation of a similar frequency of 
CCSP/Pro-SPC dual positive cells between isolated wild type and ∆E3 cell preparations. We 
conclude that use of CCSP/Pro-SPC dual positivity alone as a basis to investigate the impact of 
signaling pathways on isolated bronchiolar epithelial cells does not provide a basis for 
discrimination between rare bronchiolar stem cells and abundant facultative progenitor (Clara) 
cells107-109. We show that despite up-regulation of Pro-SPC within mature Clara cells, their 
 60 
distinguishing morphological features coupled with unique high autofluorescence characteristics 
provide a basis for their separation from low autofluorescent bronchiolar stem cells.  
Standard methods in stem cell biology include in vivo and in vitro assays to demonstrate 
self-renewal and differentiation potential of the proposed stem cell population. Even though in 
vitro models have been developed allowing propagation of tracheobronchial epithelial cells80, 
bronchiolar epithelial cells are extremely difficult to maintain and propagate in vitro. Moreover, 
no in vivo transplantation studies have been reported that allow faithful establishment of 
bronchiolar epithelium from fractionated preparations of bronchiolar cells. Fractionation 
methods allowing enrichment of bronchiolar stem cells described herein will allow further 
analysis of gene expression to define a unique molecular phenotype and will provide a basis 
upon which to build in vitro and transplantation models to assess mechanisms of self-renewal. 
Together with transgenic animal models for identification and manipulation of the stem cell 
compartment, these assays will provide critical tools to unravel the bronchiolar stem cell 
phenotype and mechanisms governing their behavior in normal and diseased lung. 
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4.0  CELL SURFACE PHENOTYPE AND FUNCTIONAL ANALYSIS OF 
BRONCHIOLAR STEM CELLS 
4.1 INTRODUCTION 
Data presented in the previous chapter indicates that CD34 is not expressed on the 
surface of epithelial cells of the lung. Moreover we showed that low levels of Sca-1 are 
expressed on the cell surface of airway epithelial cells and that high autofluorescence is a 
property of mature Clara cells of the bronchiolar epithelium. Using a transgenic animal model in 
which the bronchiolar stem cell population has been expanded, we demonstrate that bronchiolar 
stem cells are characterized by AFlow, Sca-1low, CD45neg, CD31neg, CD34neg phenotype. In vivo 
data suggests a significant expansion of stem cells in ∆E3 animals based upon the number of 
CCSP pro-SPC dual positive cells. Use of autofluorescence characteristics and cell surface 
phenotype revealed only a twofold amplification of the stem cell population. These data 
suggested that other epithelial and non-epithelial cell types are present in the AFlow, Sca-1low, 
CD45neg, CD31neg, CD34neg fraction of bronchiolar stem cells. Thus we sought to further enrich 
the stem cell fraction using other potential cell surface markers for epithelial and non-epithelial 
cell types.  
 Stem cell behavior is at least in part dictated by interactions with neighboring cells and 
subtending basement membrane that together form the stem cell niche101. Integrin and cadherin 
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family of proteins are an important part of the sensing mechanisms that dictate the proliferation, 
migration and differentiation of epithelial cells 137. Integrin expression and function have been 
widely studied in the follicular and interfollicular epidermis. Different members of the family are 
expressed constitutively or can be induced in response to epidermal injury 138. Amongst these, 
integrin α6, a member of hemidesmosomal complexes, has been shown to be expressed at high 
levels on a population of mouse epidermal and follicular stem cells, allowing their prospective 
isolation and characterization of their in vivo and in vitro properties 139,140.  
Another mediator of inter-cellular interactions shown to be expressed in other stem cell 
compartments is Epithelial cell adhesion molecule (EpCAM).  EpCAM (also known as CD326) 
is a cadherin-like transmembrane protein expressed by most epithelial cells141, including the 
lung142. Moreover, human non small cell lung carcinomas express high levels of EpCAM, 
leading to its utilization to monitor tumor progression and as a therapeutic target for tumor 
reduction143-145.  EpCAM expression has been demonstrated on the surface of oval cell 
population of liver progenitors146. Interestingly, in the human mammary gland, EpCAM and 
Integrin α6 co-expression allowed the isolation of bi-potent progenitors that in vitro have the 
ability to give rise to colonies consisting of both luminal and basal mammary cells53,147,148.  
Evidence that EpCAM and Integrin α6 can be used as cell surface markers for epithelial 
stem cells in other organ systems led us to hypothesize that epithelial-specific cell adhesion 
molecules will enable us to further enrich the bronchiolar stem cell fraction in the AFlow, Sca-
1low, CD45neg, CD31neg, CD34neg population. We show that both EpCAM and Integrin α6 are 
expressed on the cell surface of bronchiolar and alveolar epithelium and that Sca-1 expression 
allows the distinction between bronchiolar and alveolar epithelium. Moreover, we find that 
ciliated cells co-purify with the bronchiolar stem cell population in the AFlow, Sca-1low, CD45neg, 
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CD31neg, CD34neg fraction.  Functional analysis of the proliferative behavior of cells in this 
population during injury and repair allowed its localization at the top of the stem cell hierarchy.  
  
4.2 RESULTS 
4.2.1  Validation of EpCAM and Integrin alpha 6 as cell surface markers for lung 
epithelial cells 
EpCAM and Integrin α6 expression has been previously described in lung epithelial cells142. To 
validate this and enrich the epithelial fraction of the AFlow, Sca-1low, CD45neg, CD31neg, CD34neg 
population we interrogated the expression of EpCAM on the surface of lung cells isolated from 
wild type mice. EpCAM was not expressed on the surface of CD45, CD31 or CD34 positive 
cells (Figure 11). Low levels of EpCAM and CD31 or CD34 antibodies were co-expressed on 
the surface of a distinctive population (Figure 11 E and F). The EpCAM low population also 
expresses high levels of CD45, suggesting that they most likely represent a population of 
hematopoietic origin (Figure 11D). Thus, this data suggests that EpCAM is not expressed on the 
surface of CD45pos, CD31pos, CD34pos cells, and that the low levels of EpCAM in that fraction 
represent non-specific uptake by CD45pos cells, most likely macrophages. Therefore, for the 
remainder of the study the CD45pos, CD31pos, CD34pos population was excluded from the 
analysis.  
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Figure 10. EpCAM expression in single cell suspension of lung epithelial cells  
 Cells isolated from wild type animals were analyzed for EpCAM, CD45, CD31 and CD34 expression. (A) No 
EpCAM control. Biotinylated CD45 CD31 CD34 (APC-eFuor780) in the live cell population (7AAD-negative)   (B) 
No CD45 CD31 CD34 control. EpCAM PE-Cy7 expression in the live cell population. (C) Streptavidin only 
control. Non-specific binding of streptavidin APC-eFluor780 in the EpCAM PE-Cy7 stained sample.  (D) EpCAM 
PE-Cy7 expression in a CD45 APC-eFluor780 stained sample. (E) EpCAM PE-Cy7 expression in a CD31 APC-
eFluor780 stained sample. (F) EpCAM PE-Cy7 expression in a CD34 APC-eFluor780 stained sample. Dead cells 
have been excluded from the analysis based on 7AAD incorporation. Circled populations in (D)-(F) represent cells 
that co-express low levels of EpCAM PE-Cy7 and CD45 APC-eFluor780 (D), CD31 APC-eFluor780 (E) or CD34 
APC-eFluor780 (F) respectively, most likely representing non-specific binding by macrophages. In each dot plot, x-
axis represents fluorescence levels of APC-eFluor780 conjugated antibodies read in APC-Cy7 channel; y-axis 
represents fluorescence levels of PE-Cy7 EpCAM expression.  
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High levels of Integrin α6 expression have been described in some epithelial stem cell 
compartments allowing their prospective fractionation139. Thus, we interrogated the tissue 
expression of Integrin α6 and EpCAM. Immunolocalization of Integrin α6 and EpCAM in five 
micron sections from CCSPcre Rosa26LSL EYFP lungs showed that EpCAM expression is 
specific to the lung epithelium, while Integrin α6 is expressed by endothelial cells as well lung 
epithelial cells (Figure 12). Both antigens were expressed by bronchiolar epithelial cells (12B 
and D) and alveolar type II cells (12B and D). Flow cytometry analysis of the cell surface 
expression of EpCAM and Integrin α6 in isolated lung cells revealed that the majority of 
EpCAMpos cells also express Integrin α6 (Figure 12E).  Thus, these data suggest that EpCAM 
and Integrin α6 are antigens commonly expressed on the surface of bronchiolar and alveolar 
epithelial cells. EpCAM is specifically expressed on the surface of epithelial cells only, allowing 
separation of epithelial from non-epithelial fractions of total lung cells. Therefore for the 
reminder of the study we will use EpCAM as a marker for lung epithelial cells.  
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Figure 11. EpCAM and Integrin alpha 6 expression in CCSP-Cre Rosa26-LSL-eYFP lung 
epithelium 
Immunofluorescence staining of lung sections from CCSP-Cre Rosa26-LSL-eYFP transgenic animals 
demonstrating EpCAM (A) and Integrin A6 (B) expression (red). (C) and (D) overlay of native fluorescence of 
the airway epithelium (green), proSP-C (white) and EpCAM (C) or Integrin A6 (D) (200x magnification). (E) 
Flow cytometry analysis showing EpCAM PE-Cy7 (y-axis) and Integrin A6 PE (x-axis) expression on the cell 
surface of cells isolated from wild type animals showing that the majority of EpCAM positive cells also express 
Integrin α6 (gate Q2=49.9% of live cell population).   Dead cells have been excluded from the analysis. CD45pos 
CD31pos CD34pos cells have not been excluded from the analysis. Arrows point at blood vessels in A-D.  
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4.2.2 Cell surface phenotype and autofluorescence characteristics of the alveolar and 
bronchiolar epithelium 
We have previously shown that cell surface expression of Sca-1 is a property of the 
bronchiolar epithelium. Therefore, we asked whether exclusion of non-epithelial cells from the 
AFlow Sca-1low CD45neg CD31neg CD34neg based on EpCAM expression allows for further 
enrichment in bronchiolar stem cells in wild type and ∆E3 animals and if Sca-1 expression 
distinguishes alveolar from bronchiolar epithelium. Thus, cells within the EpCAMpos CD45neg 
CD31neg CD34neg fraction of wild type and ∆E3 animals  were analyzed by flow cytometry for 
cell surface expression of Sca-1 (Figure 12). Two populations were apparent in both genotypes: a 
Sca-1neg EpCAMpos population and a Sca-1low EpCAMpos population, neither of which varied 
with genotype (Figure 12 B and E). However, analysis of autofluorescence levels of the cells in 
the Sca-1low EpCAMpos in the PerCP-Cy5.5 and FITC channels (Figure 12C and F) revealed a 
twofold enrichment in AFlow cells in ∆E3 genotype compared to wild type , paralleled by a 
corresponding decrease in the AFhigh population (Figure 12 H).  
To confirm the identity of cells in each fraction, we interrogated the gene expression 
level of cell-type specific markers in wild-type cells sorted according to their cell surface 
phenotype and autofluorescence characteristics. The abundance of CCSP, SP-C and FoxJ1 
mRNAs was quantified by real-time PCR analysis of total RNA isolated from  Sca-1neg 
EpCAMpos CD45neg CD31neg CD34neg (Sca-1neg EpCAMpos), AFhigh Sca-1low EpCAMpos CD45neg 
CD31neg CD34neg (AFhi) and AFlow Sca-1low EpCAMpos CD45neg CD31neg CD34neg (AFlow) cell 
fractions (Figure 12 I-K). Sorted total live cells were used to show mRNA enrichment in each 
population and data was normalized to total lung mRNA purified from intact tissue. Thus CCSP 
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mRNA was expressed at highest levels in the AFhi population (approximately 10 fold enrichment 
relative to total isolated cells) and at considerate levels in the AFlow population (approximately 3 
fold enrichment relative to total isolated cells). This confirmed our previous data suggesting that 
CCSP expressing cells are enriched in the AFhi fraction and that a distinct sub-population of 
CCSP expressing cells are present in the AFlow fraction (Figure 4D).  
Ciliated cells and ATII cells represent fractions that potentially co-purify with 
bronchiolar stem or facultative TA (Clara) cell population. Therefore we sought to determine 
their presence in the cell populations described above. FoxJ1 is a transcription factor specifically 
expressed in ciliated cells of the bronchiolar epithelium19,149. Analysis of FoxJ1 mRNA levels 
(Figure 12K) demonstrated that ciliated cells are highly enriched in the AFlow fraction 
(approximately 50 fold enrichment relative to total isolated cells). In contrast, lower levels of 
FoxJ1 mRNA were detected in the AFhi and Sca-1neg EpCAMpos fractions suggesting that they 
were depleted of ciliated cells. This data suggested that ciliated cells co-purify with bronchiolar 
stem cells within the AFlow population. 
In vivo, surfactant protein C is expressed by alveolar type II cells, rare putative 
bronchiolar stem cells99,104. We previously determined that isolated CCSP positive cells were 
also immunoreactive for proSP-C (previous chapter). Analysis of SPC mRNA levels in the 
sorted populations (Figure 12J) showed that the Sca-1neg EpCAMpos population had the highest 
expression of SPC mRNA (approximately 6 fold enrichment relative to total isolated cells). 
Importantly, the AFlow population expressed approximately 3 times more SPC mRNA than the 
total cell population. The AFhi population expressed undetectable levels of SPC mRNA, 
confirming that the facultative TA (Clara) cells do not express SPC mRNA. As mentioned 
above, low levels of proSP-C protein were expressed in many of the CCSP immunoreactive cells 
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found in the Sca-1low CD45neg CD31neg fraction (Figure 8), which contained both AFhi and AFlow 
populations. This is the most likely reason for the absence of SP-C mRNA from the AFhi fraction 
of facultative TA (Clara) cells. Alternatively, this apparent divergence could be caused by 
differential regulation of SP-C mRNA and protein. Future experiments will address both 
possibilities. Results were confirmed using Integrin α6 as a selection marker replacing EpCAM 
(data not shown).  
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Figure 12. Cell surface expression of EpCAM and Sca-1 defines subpopulations of lung epithelial 
cells belonging to the airway and alveolar epithelium.  
Isolated cells from wild type (A)-(C) and ∆E3 mice (D)-(F) where analyzed by flow cytometry for cell 
surface expression of EpCAM PE-Cy7 and Sca-1 AF647 following exclusion of dead and CD45 CD31 CD34 
positive cells. (A) and (D) EpCAM PE-Cy7 (y-axis) and CD45 CD31 CD34 APC-eFluor780 (x-axis) expression in 
cells isolated from wild type and ∆E3 mice respectively showing. Gate P2 represents EpCAM pos CD45neg CD31neg 
CD34neg population (40.76% of live cells in (A) and 38.7% of live cells in (D)). (B) and (E) Sca-1 AF647 (x-axis) 
and EpCAM PE-Cy7 (y-axis) expression in the P2 population of wild type  and ∆E3 cells respectively. Gate P3 
defines Sca-1low EpCAMpos population and gate P4 defines the Sca-1neg EpCAMpos population. Quantification of the 
data is shown in (G) as percentage of P2. (C) and (F) Autofluorescence profile of the P3 population as seen in FITC 
and PerCP-Cy5.5 channels. HiAF and LowAF represent the high and the low autofluorescence populations 
respectively. Quantification of the data is shown in (H) as percentage of P3 population. Real time PCR data showing 
relative expression levels of CCSP(I), SPC (J) and FoxJ1 (K) in total cells (dead cells were excluded), EpCAMpos 
Sca-1neg CD45neg CD31neg CD34neg (P4 in B), AFhi EpCAMpos Sca-1low CD45neg CD31neg CD34neg (AFhi) and 
AFlow EpCAMpos Sca-1low CD45neg CD31neg CD34neg (AFlow). Data were normalized to levels of each transcript in 
total lung RNA.  
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4.2.3 Cell surface phenotype and autofluorescence characteristics of ciliated cells of the 
bronchiolar epithelium 
Ciliated cells represent a significant fraction of bronchiolar epithelial cells in the mouse 
lung. Thus identification of their cell surface and autofluorescence characteristics is necessary to 
allow their separation from the pools of lung stem and facultative TA (Clara) cells. Analysis of 
FoxJ1 mRNA levels (Figure 12) suggested that ciliated cells are enriched in the AFlow EpCAMpos 
Sca-1low CD45neg CD31neg CD34neg fraction.  
To confirm the phenotypic characteristics of the ciliated cell population, cells were 
isolated from FoxJ1 GFP transgenic animals. In these animals, GFP is a faithful reporter of 
FoxJ1 expression, leading to specific fluorescent tagging of the majority of ciliated cells19,149. 
Exclusion of dead and CD45pos CD31pos CD34pos cells in these cell preparations allowed 
evaluation of GFP expression in different fractions of epithelial cells defined according to Sca-1 
and EpCAM cell surface expression (Figure 13). Thus GFPpos cells represented 7.46% of the 
total epithelial fraction (Figure 13B), 72% of which were present in the Sca-1low EpCAMpos 
fraction. Analysis of GFP expression in the EpCAMpos Sca-1neg fraction showed that only 2.56% 
of this fraction (P7 in Figure 13C) was represented by ciliated cells, a finding consistent with the 
low levels of FoxJ1 mRNA expression observed in the Sca-1low EpCAMpos population. 
Moreover, GFPpos cells represented 19.03% of the Sca-1low EpCAMpos population (Figure 13D). 
Analysis of autofluorescence levels of the GFPpos cells in the Sca-1low EpCAMpos population 
confirmed that the majority of ciliated cells belonged to the AFlow fraction, while only small 
numbers of GFPpos cells were present in the AFhi fraction (Figure 13E). GFPpos ciliated cells 
fraction represented 33.73% of the AFlow Sca-1low EpCAMpos fraction, suggesting that ciliated 
cells co-purify with the putative bronchiolar stem cell fraction.  
 74 
 
 
 
 
 
 
 75 
 
 
Figure 13. Cell surface phenotype and autofluorescence characteristics of ciliated cells of the 
bronchiolar epithelium 
            Lungs from FoxJ1GFP transgenic mice were dissociated and analyzed by flow cytometry for GFP 
expression in the context of EpCAM and Sca-1 expression. Dead and CD45pos CD31pos CD34pos cells were excluded 
from the analysis. (A) Flow cytometry data indicating the gating strategy for the Sca-1low EpCAMpos (P4, red dots) 
and Sca-1neg EpCAMpos (P5 blue dots) populations. (B) FoxJ1 GFP expression (P8=7.46%) in the epithelial cell 
population defined as EpCAMpos CD45neg CD31neg CD34neg. (C) FoxJ1 GFP expression in the Sca-1neg EpCAMpos 
cell population (P7=2.56%). (D) FoxJ1 GFP expression in the Sca-1low EpCAMpos population (P6=19.03%). (E) 
Autofluorescence levels of the FoxJ1 GFPpos cells within the Sca-1low EpCAMpos population. AFhiGFPneg population 
represents 50.83%, AFhiGFPpos population represents 4.03%, AFlowGFPpos population represents 15.23% and 
AFlowGFPneg population represents 29.93% of the Sca-1low EpCAMpos fraction. The quantitative analysis has been 
performed on three FoxJ1 GFP animals (n=3).  
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4.2.4 SP-C GFP expression in the lung  
During development, SP-C is expressed at the tips of branching epithelium starting at 
E10.5 and its expression is restricted to the alveolar compartment late in development. In adult 
mouse lung, expression of surfactant protein C expression has long been considered a unique 
characteristic of ATII epithelial cells. Recent data suggests that bronchiolar stem cells associated 
with BADJs co-express CCSP and proSP-C in vivo99,104(Figure 7). Consistent with these results, 
mRNA isolated from epithelial cells fractionated according to their Sca-1and EpCAM expression 
status and levels of autofluorescence showed that the AFlow EpCAMpos Sca-1low (AFlow) 
population expresses both CCSP and SPC mRNA (Figure 12). To confirm SP-C expression in 
different fractions of isolated cells, we used a transgenic mouse model in which GFP expression 
is controlled by the human SP-C promoter (SP-C GFP mice). Although these mice have been 
previously used for isolation of ATII cells, GFP expression has not been thoroughly 
characterized150. Consistent with the published data, high levels of GFP expression were noted in 
ATII cells. Surprisingly, analysis of native GFP fluorescence in frozen lung sections from SP-C 
GFP mice revealed GFP expression in the bronchiolar epithelium with a spatial distribution 
consistent with stem cell niches: neuro-epithelial bodies (NEBs) and broncho-alveolar duct 
junctions (BADJs). High levels of GFP were noted at BADJs and fluorescence intensity in 
bronchiolar epithelial cells decreased and disappeared gradually in proximal bronchiolar 
epithelium (Figure 14). Proximal bronchiolar epithelium did not express GFP with the exception 
of few clusters of cells surrounding NEBs (Figure 16). To confirm the identity of the cells 
expressing high levels of GFP found at BADJs, expression of CCSP and FoxJ1 was analyzed in 
frozen lung sections from SP-C GFP transgenic mice as markers for secretory and ciliated cells, 
respectively. High levels of GFP expression co-localized with CCSP expression (Figure 15 A-C) 
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while FoxJ1 expressing cells did not express detectable levels of GFP (Figure 15 D-E). To 
determine the identity of GFP expressing cells located in clusters in the more proximal airway 
epithelium, we analyzed CCSP, FoxJ1 and CGRP expression in those locations (Figure 16). 
Immunofluorescence staining demonstrated that CCSP expressing cells around NEBs have high 
levels of GFP (Figure 16A-C). Notably, none of the FoxJ1 (Figure 16 D-F) and CGRP (Figure 
16 G-I) expressing cells expressed detectable levels of GFP. Together, these data show that in 
tissue sections of SP-C GFP lungs, GFP expression is not confined to the alveolar epithelium. 
Moreover, high levels of GFP expression were noted in CCSP expressing cells located in 
previously identified stem cell niches (NEBs and BADJs). Lower but detectable levels of GFP 
expression were noted in Clara cells of terminal bronchioles.  
Next we sought to determine GFP expression in cells isolated from SP-C GFP transgenic 
mice. Epithelial cells obtained following exclusion of dead cells and CD45pos CD31pos CD34pos 
cells were analyzed for Sca-1 and EpCAM surface expression. Consistent with previous data, the 
analysis allowed the distinction between two populations characterized by Sca-1low EpCAMpos 
(P4=28.93% of live EpCAMpos CD45neg CD31neg CD34neg) and Sca-1neg EpCAMpos (P6=63.7% 
of live EpCAMpos CD45neg CD31neg CD34neg) (Figure 17A). Analysis of GFP expression in each 
fraction revealed that the majority of cells in the Sca-1neg EpCAMpos fraction expressed high 
levels of GFP (GFPhi=90.26%) while very few cells were GFP low or negative (Figure 17B). 
Interestingly, analysis of GFP expression in the Sca-1low EpCAMpos fraction revealed two 
distinct populations, one expressing high levels of GFP (GFPhi=18.7% of EpCAMpos Sca-1low) 
and another one expressing lower levels of GFP (GFPlow=41.4% EpCAMpos Sca-1low) (Figure 
17C). Real time PCR data in Figure 12 suggested that the AFhi Sca-1low EpCAMpos population 
does not express significant levels of SP-C mRNA, while the AFlow Sca-1low EpCAMpos 
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population had high levels of SP-C mRNA. Analysis of autofluorescence levels of the GFP 
positive cells in the EpCAMpos Sca-1low population in the PerCP-Cy5.5 channel showed that a 
considerable number of AFhi cells expressed intermediate levels of GFP and that the majority of 
GFPhi cells belong to the AFlow population (Figure 17E). Together with the tissue analysis, this 
data suggests that the GFPhi cells in the EpCAMpos Sca-1low fraction represent the in vivo 
counterpart of the GFPhi, CCSP expressing cells found at BADJ and around NEBs. Future 
studies need to assess their properties during naphthalene-induced lung epithelium injury to 
determine if these cells are naphthalene resistant and if they can proliferate during the repair 
phase, characteristics previously ascribed to bronchiolar stem cells.  
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Figure 14. GFP expression in the bronchiolar epithelium of SPC GFP 
Distribution of native GFP fluorescence (green) on the proximal to distal axis in the bronchioles of SPC GFP mice.   
(B) Overlay of native GFP fluorescence with DAPI (blue) as nuclear counterstain. Arrows in (A) and (B) indicate 
cells expressing high levels of GFP at the broncho-alveolar duct junction (200x magnification). 
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Figure 15. GFP expression in bronchiolar epithelial cells found at the broncho-alveolar duct junction 
(BADJ) of SPC GFP transgenic mice.  
Immunolocalization of bronchiolar epithelium specific markers in the lungs of SPC GFP transgenic mice. (A)-(C) 
Co-localization of native GFP fluorescence (green signal in A) with CCSP (red signal in B) at the junction between 
the bronchiolar and alveolar compartment (BADJ). (C) represents overlay of (A), (B) and nuclear counterstain (blue 
signal – DAPI). (D)-(F) Immunofluorescence staining for GFP (green signal in D) and FoxJ1 (red signal in E) the of 
BADJs  of SPC GFP transgenic mice. (F) represents overlay of (D), (E) and nuclear counterstain (blue signal – 
DAPI). Images were taken at 400x magnification. Insets represent higher magnifications of BADJ cells expressing 
high levels of GFP.  
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Figure 16. GFP expression in epithelial cells surrounding neuro-epithelial bodies (NEBs) of SPC GFP 
transgenic mice.  
(A)-(C) Immunolocalization of CCSP (red in B) with the native GFP fluorescence of the bronchiolar 
epithelium around NEBs. (C) represents overlay of (A), (B) and DAPI as nuclear counterstain (blue). (D)-(F) 
Immunolocalization of FoxJ1 (red in E) and GFP (green in D) fluorescence in the bronchiolar epithelium 
surrounding NEBs. (E) represents overlay of (D), (F) and DAPI as nuclear counterstain (blue). In (A)-(E) NEBs 
were identified as CGRP expressing cell clusters in an adjacent section. (G)-(I) Immunolocalization of CGRP  
positive cells (red in H) in NEBs  surrounded by GFP expressing cells (green in G – native fluorescence) 
demonstrating mutually exclusive expression. Images represent 400 x magnifications. Insets represent higher 
magnification of the NEB area.  
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Figure 17. Cell surface phenotype of cells isolated from SP-C GFP transgenic mice  
Lungs from SP-C GFP transgenic mice were dissociated and analyzed by flow cytometry for GFP expression in the 
context of EpCAM and Sca-1 expression.(A) Flow cytometry dot plot showing the gating strategy for the EpCAMpos Sca-
1low (P4 = 28.96%, red dots) and EpCAMpos Sca-1neg (P6 = 63.7%, blue dots) populations. To minimize the cross-
contamination of cells from the two different fractions gates were drawn further apart. (B) Histogram representation of 
GFP expression in the EpCAMpos Sca-1neg fraction showing that the majority of cells express high levels of GFP (GFPhi = 
90.26%  and GFPlow = 2.26% of  the EpCAMpos Sca-1neg fraction). (C) Histogram representation of GFP expression in 
the EpCAMpos Sca-1low fraction showing the distribution of cells between GFPhi and GFPlow fractions (GFPhi = 18.7% 
and GFPlow = 41.4% of the EpCAMpos Sca-1low fraction). (D) Overlay of (B) and (C) allows the comparison of GFP 
fluorescence levels and number of GFP expressing cells in each population. (E) Analysis of autofluorescence levels as a 
function of GFP expression in the EpCAMpos Sca-1low fraction. Quadrants are labeled according to their autofluorescence 
and GFP status as follows: AFhi GFPneg = 7.93%, AFhi  GFPpos = 46.33%, AFlow GFPneg = 29.86%, AFlow GFPpos 
= 15.86% of the  EpCAMpos Sca-1low population. Dead cells and EpCAMneg CD45pos CD31pos CD34pos cells were excluded 
from the analysis. Quantitative analysis represents the results from cells isolated from three SP-C GFP transgenic mice.  
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4.2.5 Functional analysis of the proliferative behavior of the AFhi and AFlow populations 
during naphthalene injury and repair 
Data presented in the previous chapter suggest that the two components of the EpCAMpos 
Sca-1low population, the AFhi and the AFlow fractions, represent functionally distinct progenitor 
pools of facultative TA (Clara) cells and bronchiolar stem cells, respectively. The main 
distinction between Clara and stem cell populations in vivo is their behavior in response to 
airway injury. Thus, the facultative TA (Clara) cells metabolize naphthalene and are depleted 
within the first 24 hours after naphthalene administration. In contrast, the bronchiolar stem cells 
are naphthalene resistant and proliferate to repair naphthalene injured airways. Ciliated cells, 
which co-purify with bronchiolar stem cells in the AFlow fraction, survive naphthalene injury and 
squamate to cover the basement membrane until epithelial integrity is restored18,55,151.  
Thus, to reveal functional differences between cell types represented within the AFhi and 
AFlow populations, the abundance and proliferative capacity of cells within the two fractions 
were studied during naphthalene injury and repair. Changes in the abundance of the AFhi 
population during naphthalene injury were assessed by flow cytometry. Cells were isolated from 
lungs of C57B6 male mice two days after exposure to 250mg/kg naphthalene (Figure 18). In 
control animals, analysis of autofluorescence levels in the PE and APC channels revealed a 
distinct AFhi population that accounted for 12.1% of the live CD45neg CD31neg population 
(Figure 18A). In contrast, autofluorescence analysis of cells isolated from naphthalene treated 
mice revealed an approximate 70% decrease in the size of the AFhi population which accounted 
for only 3.56% of the live CD45neg CD31neg population (Figure 18B and C) confirming that cells 
within the AFhi fraction represent mostly naphthalene-sensitive Clara cells.  
 87 
To study the proliferative capacity of cells within the AFhi and AFlow fractionss, mice 
were exposed to naphthalene followed by a 72 hour period of BrdU administration. Cells isolated 
from lungs of uninjured control mice and mice recovered for 3 days after naphthalene 
administration were analyzed for EpCAM and Sca-1 expression (Figure 19). EpCAM expression 
is limited to the epithelial compartment of the lung, thus making exclusion of CD45, CD31 and 
CD34 expressing cells unnecessary. Analysis of the abundance of EpCAMpos Sca-1low cells 
showed a drastic decrease in this fraction in naphthalene injured compared to control animals. A 
slight decrease in the number of Sca-1neg EpCAMpos cells was noticed representing a dilution 
caused most probably by an influx of inflammatory cells (Figure 19 A-C). This data 
demonstrated efficient injury of the bronchiolar epithelium. Next, the number of cells that 
proliferated during the first 72 hours after naphthalene administration was determined in the Sca-
1low EpCAMpos and Sca-1neg EpCAMpos populations by analysis of BrdU incorporation. Very low 
numbers of BrdU incorporating cells were detected in control animals (P4=2.7% of Sca-1low 
EpCAMpos population and P5=0.766% of Sca-1neg EpCAMpos population in Figure 19 D and E 
respectively), confirming the quiescence of the steady state lung epithelium. The number of 
BrdU incorporating cells in the Sca-1low EpCAMpos population 3 days after naphthalene injury 
was significantly increased (P4= 20.33% of Sca-1low EpCAMpos population Figure 19 F). This 
demonstrates that naphthalene resistant cells in the EpCAMpos Sca-1low fraction have a high 
proliferative potential, consistent with the expected behavior of the bronchiolar stem cell 
population. We next sought to determine the autofluorescence levels of BrdU incorporating cells 
in the EpCAMpos Sca-1low fraction of control and injured mice. Analysis of BrdU positive cells 
(FITC channel) as a function of autofluorescence in PerCP-Cy5.5 channel revealed four 
populations (Q1- BrdUneg  AFhi, Q2- BrdUpos AFhi, Q3 – BrdUneg  AFlow and Q4 – BrdUpos  AFlow 
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populations, Figure 19 I-L). In cells isolated from uninjured animals, the few BrdUpos cells were 
uniformly distributed between the AFlow and AFhi fractions (Q2 and Q4) suggesting that both 
populations participate, albeit at very low levels, to normal homeostatic maintenance of the 
airway epithelium. Whether BrdU incorporating cells in the AFlow fraction represent proliferating 
stem cells or nascent ciliated cells, remains to be determined. Comparison of the BrdUneg 
fractions (Q1 and Q3 in Figure 19 I, J and K) between uninjured and injured animals confirmed 
the decrease in the AFhi population following injury as shown in Figure 18. Interestingly, 
analysis of the distribution of BrdU incorporating cells in injured animals demonstrated that the 
majority of BrdUpos cells were present in the AFlow fraction, with an almost 10 fold increase in 
number compared with uninjured controls (Q2 and Q4 in Figure 19 I, J and L). Together these 
data demonstrate that the AFhi EpCAMpos Sca-1low population represents the naphthalene-
sensitive facultative TA (Clara) cell population and that the AFlow fraction of the EpCAMpos Sca-
1low population represents naphthalene resistant, highly proliferative stem cell population 
responsible for the initiation of the repair process following naphthalene injury.  
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Figure 18. Changes in the abundance of AFhi population during naphthalene injury. 
Adult male mice were treated with naphthalene (250mg/kg). Two days later cells were isolated from 
naphthalene treated and untreated (control) lungs (n=3 mice per condition) and the abundance of the AFhi 
population in the live cell population was analyzed and compared between groups.  (A) Flow cytometry analysis of 
autofluorescence levels of cells isolated from a control (untreated) mouse. (B) Flow cytometry analysis of 
autofluorescence levels of cells isolated two days after naphthalene administration. The gate defines the high 
autofluorescence (AFhi) population in (A) and (B). (C) Quantitative representation of data in figure (A) and (B).   
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Figure 19. Proliferation during the repair process following naphthalene injury. 
                     Adult male mice were treated with naphthalene (250mg/kg). BrdU was administered i.p. to treated and 
untreated controls every 12 hours for 72 hours after naphthalene administration. Mice were sacrificed 2 hours after 
the last i.p. administration, cells were isolated and analyzed by flow cytometry for BrdU incorporation in the 
context of the Sca-1 and EpCAM cell surface expression. (A)-(C) Flow cytometry analysis of EpCAM PE-Cy7 (y 
axis) and Sca-1 Alexa Fluor 647 (x axis) in the live cell population of control (A) and day3 after naphthalene injury 
(B) animals. P2 gate (red dots) represents the Sca-1low EpCAMpos population and P3 gate (blue dots) represents the 
Sca-1neg EpCAMpos population. (C) Quantitative representation of data in (A) and (B) showing the abundance of 
cells in P2 and P3 populations in cells isolated from control (dark red and blue bars) and day 3 after naphthalene 
injury (light red and blue bars). (D) – (H) Proliferation in the P2 (red histograms) and P3 (blue histograms) cell 
populations in control and naphthalene treated mice. Flow cytometry histograms demonstrating the number of BrdU 
incorporating cells in cells isolated from control (D and E) or day 3 after naphthalene treatment (F and G) mice. 
Gates P4 and P5 represent the BrdUpos fractions of the Sca-1low EpCAMpos (P2) population and Sca-1neg EpCAMpos 
(P3) respectively. (H) Quantitative analysis of the number of BrdUpos cells in (D) – (G) in control (dark blue and red 
bars) and naphthalene treated (light blue and red bars) mice. (I) – (L) Analysis of autofluorescence levels of the Sca-
1low EpCAMpos (P2 in A and B) in the PerCP-Cy5.5 and FITC channels in control (I) and naphthalene treated 
animals (J). Q1- AFhi BrdUneg , Q2 - AFhi BrdUpos , Q3 – AFlow BrdUneg, and Q4 – AFlow BrdUpos. (K) Quantitative 
representation of gates Q2 and Q4 in control (dark red bars) and naphthalene treated animals (light red bars). 
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4.2.6 Functional analysis of the proliferative behavior of the AFhi and AFlow populations 
during ozone injury and repair 
The progenitor function of the abundant pool of Clara cells (termed here facultative TA 
cells) in the rodent lung has been demonstrated in classical studies involving ozone injury2. 
Ozone exposure causes lung epithelial cell damage, ciliated cells being the most sensitive cells. 
Evans et al. demonstrated that ablation of ciliated cells by exposure to ozone causes Clara cells 
to undergo morphological changes, proliferate and restore the ciliated cell pool. Thus the 
progenitor-progeny relationship between Clara cells and ciliated cells was established2. We have 
shown in the previous chapter that the AFhi EpCAMpos Sca-1low CD45neg CD31neg CD34neg 
population consists of naphthalene-sensitive cells and that AFlow EpCAMpos Sca-1low CD45neg 
CD31neg CD34neg cells represent the naphthalene resistant stem cells that proliferate during the 
repair response. To demonstrate the facultative progenitor function of the AFhi EpCAMpos Sca-
1low fraction, ciliated cells were depleted by means of ozone exposure. Adult male mice were 
exposed to 1.5ppm Ozone for 12 hours, and control mice were exposed to filtered air (FA) for 
the same length of time. To label proliferating cells, mice in both groups were treated with BrdU 
for the first 48 hours of recovery and sacrificed 2 hours after the last BrdU administration (Figure 
19).   As expected, analysis of EpCAM and Sca-1 expression in the live cell population revealed 
two populations of EpCAMpos Sca-1low and EpCAMpos Sca-1neg. Interestingly, the EpCAMpos 
Sca-1low population showed a significant increase 48 hours after ozone exposure (P2=10.25% vs 
15.23% of live cells in FA exposed and ozone treated mice respectively), while the EpCAMpos 
Sca-1neg population did not change significantly (P3=26.75% vs 29.26% of live cells population 
in FA and ozone treated mice respectively). This increase was most likely caused by an ample 
proliferative response of the Clara cell population that exceeded the needs for ciliated cell 
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replacement, thus resulting in an overall increase in number of bronchiolar epithelial cells. Thus, 
the number of cells that proliferated during the 48hours of BrdU administration was evaluated in 
each fraction. The number of BrdU incorporating cells in the EpCAMpos Sca-1neg fraction was 
very low in FA controls and did not increase significantly following ozone exposure (P5=0.6% 
versus 0.46%), suggesting that the alveolar compartment was not impacted by ozone exposure.  
However, evaluation of the proliferating pool in the EpCAMpos Sca-1low population showed an 
almost four fold increase in percentage of BrdUpos cells in ozone treated mice compared with FA 
controls (P5=3.1% versus 11.06%), consistent with the expected behavior of bronchiolar 
epithelial cells. To determine the autofluorescence characteristics of BrdUpos cells in the 
EpCAMpos Sca-1low population, BrdU FITC expression in that fraction was evaluated as a 
function of autofluorescence in PerCP-Cy5.5 channel. The number of BrdUneg cells in the AFlow 
and AFhi populations (Q1 and Q3 in figure 20K) was not altered in response to ozone injury, thus 
demonstrating that the increase in total number of cells in the EpCAMpos Sca-1low fraction 
observed in ozone exposed mice is indeed the result of proliferative events that took place in the 
48hours of BrdU administration. Interestingly, BrdUpos cells in ozone treated mice were present 
in both AFhi and AFlow fractions, suggesting that both the stem and the facultative TA 
compartments participate to the repair response following ozone injury (populations Q2 and Q4 
in figure 20L). However, BrdU incorporating facultative TA (Clara) cells that differentiated and 
gave rise to ciliated cells represent another possible source of BrdUpos cells in the AFlow fraction. 
Importantly though, the significant number of cells in the AFhi fraction incorporated BrdU label 
following ozone injury, demonstrating its proliferative ability and progenitor function.  
Ozone injury has been shown to induce proliferation in CCSP expressing secretory cells 
in the bronchiolar epithelium, without distinguishing between stem and facultative TA (Clara) 
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cells. Analysis of the autofluorescence levels of cells proliferating in response to ozone injury 
suggested that both the stem and the facultative TA (Clara) cell pools participate in the repair 
process. Thus we analyzed the localization of BrdU incorporating cells in lung sections from FA 
and ozone exposed mice as a function of known lung epithelial specific markers (Figure 21). As 
expected, the number of proliferating cells in FA exposed animals was very low. Interestingly 
though, exposure to ozone induced proliferation preferentially in the distal bronchiolar 
epithelium, while the proximal epithelium was mainly quiescent with the exception of occasional 
foci of proliferating CCSP expressing cells (Figure 21 A-F). Importantly, we were able to 
demonstrate the presence of proliferating cells within both previously characterized stem cell 
niches, BADJs and NEBs (Figure 21 F and L) as well as CCSP expressing cells outside of these 
niches. Consistent with the flow cytometry analysis, proliferation in the alveolar epithelium 
compartment was very low; the majority of proliferating cells in that location most likely 
represented inflammatory cells (Figure 21 G-J).  
Thus, we used two distinct injury models to reveal the functional differences between the 
AFhi and the AFlow fractions of the EpCAMpos Sca-1low population of bronchiolar epithelial cells. 
Together, these data demonstrate that the AFlow population represents naphthalene resistant cells, 
that participates in the repair response following both naphthalene and ozone injury, validating 
their stem cell characteristics. The AFhi population consists of naphthalene sensitive cells that 
have proliferative capacity in response to ozone exposure demonstrating their facultative 
progenitor behavior.  
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Figure 20. Proliferation during the repair process following ozone injury. 
            Adult male mice were exposed to 1.5ppm ozone for 12 hours and recovered for 48 hours in room air. 
Control mice were exposed to 1.5ppm filtered air (FA) for 12 hours and recovered for 48 hours in room air. BrdU 
was administered i.p. to animals in both groups every 12 hours for the 48 hours of recovery. Mice were sacrificed 2 
hours after the last i.p. administration, cells were isolated and analyzed by flow cytometry for BrdU incorporation in 
the context of the Sca-1 and EpCAM cell surface expression. (A)-(C) Flow cytometry analysis of EpCAM PE-Cy7 (y 
axis) and Sca-1 Alexa Fluor 647 (x axis) in the live cell population of control FA (A) and ozone exposed animals (B). 
P2 gate (red dots) represents the Sca-1low EpCAMpos population and P3 gate (blue dots) represents the Sca-1neg 
EpCAMpos population. (C) Quantitative representation of data in (A) and (B) showing the abundance of cells in P2 
and P3 populations in cells isolated from control FA (dark blue and red bars) and ozone exposed mice (light blue and 
red bars)( P2=10.25% and 15.23% and P3=26.72% and 29.26% of live cell population in FA or ozone expose mice 
respectively). (D) – (H) Proliferation in the P2 (red histograms) and P3 (blue histograms) cell populations in control 
FA and ozone exposed mice. Flow cytometry histograms demonstrating the number of BrdU incorporating cells in 
control FA (D and E) or ozone treated (F and G) mice. Gates P4 and P5 represent the BrdUpos fractions of the Sca-1low 
EpCAMpos (P2) population and Sca-1neg EpCAMpos (P3) respectively. (H) Quantitative analysis of the number of 
BrdUpos cells in (D) – (G) in control FA (dark red and blue bars) and ozone treated (light red and blue bars) mice 
(P4=3.1% and 11.06% and P5=0.6% and 0.466%). (I) – (L) Analysis of autofluorescence levels of the Sca-1low 
EpCAMpos (P2 in A and B) in the PerCP-Cy5.5 and FITC channels in control FA (I) and ozone exposed mice (J). Q1- 
AFhi BrdUneg , Q2 - AFhi BrdUpos , Q3 – AFlow BrdUneg, and Q4 – AFlow BrdUpos. (K) Quantitative representation of 
gates Q2 and Q4 in FA (dark red bars) and ozone treated animals (light red bars) (Q2=1.8% and 5.56% and Q4=1.7% 
and 6.83%). 
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Figure 21. Tissue localization of cells proliferating in response to ozone injury 
Adult male mice were exposed to 1.5ppm ozone for 12 hours and recovered for 2 or 10 days in room air. 
Control mice were exposed to filtered air (FA) for 12 hours and recovered for the same amount of time in room air. 
BrdU was administered i.p. to animals in all groups every 12 hours for the first 48 hours of recovery. The identity of 
the proliferating cells was determined by immunofluorescence co-localization of BrdU (green signal) and other cell 
type specific markers (red signal). (A) – (F) Proliferation in the airway epithelium. BrdU (green A-F) CCSP (red B, 
D and F) immunolocalization in lung sections of control FA exposed mice (A and B), proximal airways of ozone 
exposed mice (C and D) and distal airways of ozone exposed mice (E and F). Inset in F shows higher magnification 
of a BADJ area (200 x magnification). (G) – (J) Immunofluorescence staining for BrdU (green) and proSP-C (red) 
of terminal bronchioles (G and H) and gas exchange area (I and J) of ozone exposed mice (200x magnification). 
Insets in (H) and (J) represent higher magnifications of a BADJ (H) and gas exchange area (J). (K) and (L) 
Immunofluorescence detection of BrdU (green) and CGRP (red) in neuro-endocrine bodies of ozone exposed mice 
(400x magnification). Inset in (L) represents higher magnification of the NEB area. DAPI – nuclear counterstain 
(blue signal in overlayed images). Arrows in F, H, J and L point at areas magnified in insets.  
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4.3 DISCUSSION 
Expression of a unique repertoire of cell surface markers has been extensively used as a 
tool to prospectively isolate and characterize stem and progenitor populations in several organs. 
Moreover, it represents a pre-requisite of stem cell isolation aimed at development of cell-based 
therapies. The goal of this study was to define characteristics of bronchiolar stem cells that allow 
their prospective isolation to better understand their functional behavior in steady state and 
injured lung. In this chapter we provide evidence for expression of Sca-1, EpCAM and Integrin 
α6 on the cell surface of distinct populations of lung epithelial cells. EpCAM and Integrin α6 
allow the distinction between epithelial and non-epithelial cells within the Sca-1low population. 
Gene expression analysis validated by the use of transgenic mouse models expressing fluorescent 
reporters allowed the identification of cell surface phenotype and autofluorescence 
characteristics of most epithelial cell types in the lung. Thus we define an EpCAMpos, Integrin 
α6pos, Sca-1neg, CD45neg, CD31neg, CD34neg population that represents mostly alveolar epithelial 
cells. Bronchiolar epithelial cells are characterized by EpCAMpos, Integrin α6pos, Sca-1low, 
CD45neg, CD31neg, CD34neg phenotype and they can be further fractionated according to their 
autofluorescence characteristics into AFhi and AFlow populations. Epithelial injury and repair 
models demonstrate that cells within the two populations are functionally distinct. The AFhi 
fraction behavior was indicative of a facultative progenitor population, while the behavior of the 
AFlow fraction suggested a stem cell phenotype. Ciliated cells of the bronchiolar epithelium were 
present in the AFlow fraction, indicating that they are a significant fraction that co-purifies with 
the bronchiolar stem cell population.  
Validation of stem cell characteristics of a specific cell population includes analysis of its 
in vivo, in vitro and transplantation properties that would confirm their progenitor cell function. 
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Self renewal and differentiation abilities of a putative stem cell population can be demonstrated 
in clonogenic and serial passage in cultured and transplanted cells30, 51. Unfortunately, robust and 
reproducible in vitro and transplantation assays for lung epithelial cells do not exist, thus making 
it impossible to test the functional properties of the AFhi and AFlow fractions of the EpCAMpos 
Sca-1low CD45neg CD31neg CD34neg cell populations in such assays.  In vivo bronchiolar stem 
cells have been identified based on their resistance to naphthalene injury and proliferative 
capacity during airway repair response18, 55. Thus we have been able to demonstrate that the AFhi 
population is naphthalene sensitive and that the AFlow population is naphthalene resistant and it 
incorporates BrdU label during the initial phases of the repair response (Figure 22 C). Moreover, 
Clara cells have been shown to serve as progenitors for the terminally differentiated ciliated cells 
following ozone injury2. In our studies, we used a relative high concentration of ozone for 
extended periods of time (1.5ppm ozone for 12 hours) and we can show that we elicited a 
proliferative response from both the stem and the facultative TA (Clara) cell populations (Figure 
22 B). Although these data does demonstrate the progenitor functions of the AFhi fraction, it also 
shows for the first time that ozone can induce proliferation in the stem cell compartment. Future 
studies will evaluate the dose dependency and the types of injury that ozone causes as well as the 
proliferative response it induces. Naphthalene and ozone injury and repair studies were designed 
to determine the characteristics of cells that incorporated BrdU label during the initial repair 
response (Figure 22). However, our analysis does not indicate the number and phenotype of cells 
that actively proliferate at the time of the analysis, but it allows us to determine the fate and 
phenotype of cells that have proliferated during the labeling period. It is possible, for example, 
that a stem cell originally belonging to the AFlow population, incorporated BrdU early during the 
labeling period and matured into a facultative TA (Clara) cell, found in the AFhi population at the 
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time of the analysis. Conversely, a facultative TA (Clara) cell in the AFhi fraction can incorporate 
BrdU during a proliferation event that generates a BrdUpos ciliated cell, found in the AFlow 
fraction at the time of the analysis. Pulse labeling experiments (one i.p. administration of BrdU 2 
hours before sacrificing the animal) will accurately determine the size of the actively 
proliferating pool. Comparison of the results from continuous and instantaneous labeling 
following naphthalene and ozone injury will reveal important information about the number and 
the fate of proliferating cells in each fraction. 
Another proposed in vivo characteristic of the bronchiolar stem cell found at BADJs is 
dual expression of two proteins characteristic for ATII and bronchiolar secretory cells, SP-C and 
CCSP respectively99,104. Their presence in vivo and their direct relationship with bronchiolar 
stem cells are still a matter of debate. Technical hurdles related to the quality of antibodies used, 
the low levels of expression of both proteins and the autofluorescence of the bronchiolar 
epithelium made it difficult to draw definitive conclusions in regard to their existence and 
functional properties. Moreover, the existence of such dual expressing cells in the other stem cell 
niche (NEBs) has not been assessed before. To confirm the presence of dual expressing cells in 
the AFlow fraction, we used a transgenic animal model expressing GFP under the human SP-C 
promoter150. Interestingly, analysis of native fluorescence showed GFP expression in the airways 
of SP-C GFP transgenic mice. Fluorescence levels were high at BADJs and faded proximally, 
with the exception of CCSP expressing cells located around NEBs. Whether those cells represent 
naphthalene resistant cells and proliferate to repair the epithelium remains to be addressed in 
future studies. Expression of the GFP transgene does not necessarily parallel the endogenous 
gene or protein expression but it does raise the interesting possibility that the SP-C promoter is 
active and can be activated in certain circumstances. Most importantly, the value of this 
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transgenic animal model is that together with the cell surface characteristics described in the 
chapter, it will allow the prospective isolation of cells located in stem cell niches. Future studies 
will evaluate the in vitro and in vivo functional properties as well as the gene expression 
signature of the cell populations described in this chapter.  
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Figure 22. Schematic representation of the structure of the bronchiolar stem cell hierarchy 
The model represents hierarchical organization of the bronchiolar stem cell hierarchy based upon 
autofluorescence and functional characteristics in steady state (A) and injured (B) and (C) airway epithelium. (A) 
Steady state airway epithelium encompasses two distinct populations based upon autofluorescence characteristics: a 
population characterized by high autofluorescence (AFhi – light green) that comprises of facultative TA (Clara) cells 
and a population characterized by low autofluorescence (AFlow – dark green) comprising of bronchiolar stem cells 
(Stem cell) and terminally differentiated ciliated cells (Ci). The transit amplifying population (TA) represents an 
intermediate between the stem and the facultative TA (Clara) cells that holds the ability to generate terminally 
differentiated ciliated cells. (B) Representation of the functional behavior of BrdU (red dots) incorporating cells in 
the AFhi and AFlow fractions during the repair response following ozone exposure shows that both stem and 
facultative TA can give rise to the TA intermediate that replenishes the pool of terminally differentiated ciliated 
cells. Graph: see Figure 20K, in each group, left bar represents BrdU incorporation in FA controls (C) and right bar 
represents BrdU incorporation in O3 injured mice (I). (C) Representation of the functional behavior of BrdU (red 
dots) incorporating cells in the AFhi and AFlow fractions during the repair response following naphthalene injury 
showing that the AFlow population of stem cells is responsible for the majority of BrdU incorporating cells. Graph: 
see Figure 19K; in each group left bar represents BrdU incorporation in uninjured controls (C) and right bar 
represents BrdU incorporation in naphthalene injured mice (I). Cells lined by dotted line represent cells depleted 
during injury (ozone sensitive (B) and naphthalene sensitive (C) cells). 
 
 
 104 
5.0  SUMMARY, CONCLUDING REMARKS, AND FUTURE DIRECTIONS 
The main goal of our study was to define characteristics specific to the bronchiolar stem 
cell population that would allow their prospective isolation and further characterization towards a 
better understanding of how they participate in lung disease pathogenesis and of their therapeutic 
potential. We have been able to demonstrate that previously proposed cell surface markers do not 
accurately define the bronchiolar stem cell population. In the absence of robust in vitro and 
transplantation assays, we used transgenic animal models associated with stem cell expansion, 
ablation and lineage tracing to validate fractionation strategies leading to enrichment of distinct 
populations of lung progenitor and stem cells. The stem and progenitor properties of these 
populations have been validated using previously established injury and repair models. Thus, we 
have been able to identify three distinct populations of lung epithelial cells: 1) a population 
defined by EpCAMpos Sca-1neg CD45neg CD31neg CD34neg phenotype that consists mostly of 
alveolar type II cells; 2) a population defined by AFhi EpCAMpos Sca-1low CD45neg CD31neg 
CD34neg that consists mainly of the facultative TA (Clara) cell population and 3) a population 
defined by AFlow EpCAMpos Sca-1low CD45neg CD31neg CD34neg that contains the majority of 
ciliated cells as well as the bronchiolar stem cell population.  
 Future studies need to assess the functional properties of prospectively isolated 
stem and progenitor cell populations in vitro and in transplantation assays, and define the gene 
expression signature of the stem cell population.  
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Culture conditions supporting the growth and expansion of mouse bronchiolar epithelial 
cells are currently unknown. In other systems, cell culture experiments were able to reveal 
differences between stem cells and more differentiated progenitors based on the size of the 
generated clones (holoclones vs meroclones in the skin65), their clonogenic frequency, i.e. the 
frequency with which cells give rise to colonies, and serial passage ability, the ability to re-form 
colonies upon passaging51,152.We are currently conducting experiments towards defining 
culturing conditions for bronchiolar epithelial cells. The cell specific markers available to 
determine the identity of cultured epithelial cells are mostly secreted proteins (CCSP and SP-C) 
and their expression is down-regulated in culture, making it impossible to determine the identity 
of the growing cells. In that regard, transgenic animal models that allow lineage tracing of cells 
within the bronchiolar epithelium represent an invaluable tool to follow the fate of cultured 
epithelial cells. In bronchiolar epithelium both stem and facultative TA (Clara) cells have 
proliferative ability and the distinction between the two has been established in vivo based upon 
the relative resistance of the stem cells to naphthalene injury. It is currently unknown whether 
this stem cell property is conferred by the protective environment of the stem cell niche or if it is 
a cell-intrinsic property. Therefore, there is a strong possibility that when removed from their 
native environment, functional differences between stem and facultative TA (Clara) cells are 
abrogated. Culture conditions have a profound influence on the proliferative and differentiation 
choices of cells that are not necessarily reflective of their in vivo properties. Thus, interpretation 
of cell culture outcome must be approached with caution and all the above mentioned factors 
must be taken into consideration. The appropriate combination of substrates and medium 
components will need to be defined for self renewal and differentiation assays. Preliminary 
studies have been successful in the propagation of lineage tagged cells on Matrigel basement 
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membrane extract and on NIH 3T3 J2 cells (Figure 23). Lineage tagged epithelial cells formed 
sphere-like structures when grown on Matrigel and three dimensional colonies of cells when 
grown on NIH 3T3 J2 cells. Both of these substrates were previously used for propagation of 
other stem cell populations like epidermal stem cells (NIH 3T3 J2) and mammary and prostate 
stem cells (Matrigel) 51, 52,153,154. Ongoing studies aim at optimizing culturing conditions 
permissive for propagation and serial passage of bronchiolar epithelial cells that would reflect 
the functional differences between stem and facultative TA cells observed in vivo. 
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Figure 23. Outline of the selection strategy leading to prospective isolation of sub-populations of lung 
epithelial cells. 
The model summarizes steps taken towards identification of positive and negative selection markers used 
to prospectively isolate facultative TA (Clara) cells (purple discs), alveolar type II (ATII) cells (blue discs), ciliated 
cells (yellow discs) and bronchiolar stem cells (orange discs). The selection strategy includes negative selection of 
cells of hematopoietic (CD45pos) and endothelial (CD31pos) origin (grey discs, Figure 1C), CD34pos cells (green 
discs, Figures 6 and 9) and non-epithelial cells (EpCAMneg purple discs, Figures 10-13). Sca-1 expression 
distinguishes alveolar epithelium (Sca-1neg, blue discs, Figures12 and 17) from bronchiolar epithelial cells (Sca-1low, 
Figure 12). Amongst airway epithelial cells, autofluorescence characteristics distinguish facultative TA (Clara) cells 
which are AFhi (magenta discs, Figure 12) from bronchiolar stem cells (orange discs) and ciliated cells (yellow 
discs) which are AFlow (Figures 12 and 17).  
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Figure 24. Cell culture assays supporting growth of lung epithelial cells 
Cells were isolated from the lungs of wild-type (A), CCSPcre Rosa26 LSL EYFP (B) and SP-Ccre Rosa26 
TdTomatoflox/flox EGFP (C) and cultured on Matrigel (A) and (B) and on NIH3T3 J2 fibronblasts (C).  
(A). Nuclear fast red staining of a spheroid 21days into the Matrigel culture. (B) Confocal microscopy 
image of a spheroid derived from lineage traced airway epithelial cells (CCSPcre Rosa26 LSL EYFP) demonstrating 
the airway epithelium origin of cells forming spheroids. (C) Z-stack confocal images of cells from lineage traced 
lung epithelial cells (SP-Ccre Rosa26 TdTomatoflox/flox EGFP) cultured on Mitomycin C treated NIH 3T3 J2 for 7 days. 
Red cells (TdTomato) represent unrecombined non-epithelial cells and green cells (EGFP) recombined lung 
epithelial cells. The SP-Ccre transgene is activated in lung epithelium early in development (approximately E10.5), 
thus inducing recombination and lineage tracing of the entire intra-pulmonary lung epithelium (airways and alveolar 
epithelium).  
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Transplantation assays are critical to demonstrate the functional properties of a stem cell 
population as they provide an environment more closely related to the native environment of the 
population studied. Future studies need to define the optimal conditions that promote 
propagation of lung epithelial cells. Good examples include intra-tracheal administration of cells 
or injecting cells subcutaneously or under the kidney capsule. Survival, proliferation and 
differentiation of bronchiolar stem cells are expected to be greatly influenced by the 
environment. The properties of the bronchiolar stem cell niche are largely unknown and the 
mechanisms involved in stem cell maintenance and activation remain to be explored. To provide 
the best chances for the bronchiolar stem cell to survive and proliferate we used a novel 
technique involving subcutaneous co-transplantation of mixed fluorescently tagged bronchiolar 
epithelial cells and untagged undifferentiated mouse embryonic (ES) stem cells. When 
transplanted subcutaneously, undifferentiated ES cells randomly differentiate towards all known 
lineages and give rise to teratomas. We hypothesized that on their way to differentiating towards 
endodermal lineage the ES cells would provide an environment appropriate for maintenance and 
growth of bronchiolar stem cells. Thus we isolated lung epithelial cells from transgenic mice 
expressing ubiquitously TdTomato, mixed them with untagged undifferentiated ES cells and 
transplanted them subcutaneously under the skin of immuno-deficient mice. Teratomas were 
collected three weeks later and analyzed for the presence of TdTomato positive cells. 
Interestingly, clusters of TdTomato positive cells were found organized in tubular structures that 
expressed CCSP, proSP-C or both (Figure 24). Moreover, ES cell derived tubular structures that 
expressed proSP-C were also present. They were underlined by TdTomato mesenchymal cells, 
suggesting that lung fibroblasts can influence the differentiation of ES cells towards lung 
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epithelium. Future experiments performed with sorted population (AFhi and AFlow) will address 
the functional properties of the stem and facultative progenitor cell pools.  
Our studies indicate that the AFhi and AFlow populations are functionally and 
phenotypically different. In order to refine our understanding of the differences between these 
populations and find novel cell surface markers that would allow further enrichment in 
bronchiolar stem cells in the AFlow fraction, we will perform microarray analysis on mRNA 
isolated from sorted populations. Ciliated cells, which are also present in the AFlow population, 
will be excluded using FoxJ1 GFP transgenic mice.  
In conclusion, the work presented here provides new information defining bronchiolar 
cells with phenotypic characteristics of stem cells, opening the door for development of novel 
assays to evaluate the status of the bronchiolar stem cell compartment in healthy and disease 
states. An important future direction consists of translational research that will eventually lead to 
improved therapeutic interventions and a better understanding of pathogenetic mechanisms of 
human lung disease. In that regard, solid in vitro and transplantation assays become instrumental 
in transitioning from mouse to human lung science to improve our understanding of human lung 
biology.  
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Figure 25. Lung epithelial cells transplantation assay 
Cells isolated from lungs (total cell population) of ubiquitous TdTomato expressing mice (Rosa26 
TdTomatoflox/flox EGFP) were mixed with undifferentiated ES cells and transplanted under the skin of immuno-
deficient mice. Three weeks later the teratomas were harvested, sectioned and stained for CCSP (purple), proSP-C 
(green). (A) (B) Immunofluorescence staining for CCSP (purple) and proSP-C (green) of an epithelial tubular 
structure derived from transplanted lung cells (red – TdTomato) showing that teratomas are permissive for airway 
epithelial cells growth. (C) Immunofluorescence staining for CCSP (purple) and proSP-C (green) of an epithelial 
structure derived from differentiating ES cells underlined by lung derived mesenchymal cells (red – TdTomato), 
suggesting that adult lung mesenchyme can direct differentiation of ES cells into lung epithelium. Blue signal 
represents DAPI counterstain. (A) and (B) 400x magnification and (C) 200x magnification.  
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APPENDIX A 
A.1 CELL ISOLATION PROCEDURE 
Materials: 
• Dissection instruments 
• Dissection board 
• Canula: 20GA 1.16IN (BD) 
• 2 X 1ml seringe 
• 1X 10ml seringe 
• 4-0 silk 
• Anesthetic 
• Ice bucket  
• 50ml conical tubes 
• 1XPBS (perfusion) 
• 1XPBS 0.2mM EGTA (Lavage) 
• Ham’s F12 
• 0.2um Syringe filter (Nalgene) 
• 70um Nylon Cell Strainer (BD Falcon) 
• HBSS  
• HBSS+ ( HBSS, 10mMHEPES pH 7, 2%FBS) 
• FBS 
• DNase I 
• Elastase (4U/ml in Ham’s F12) – Worthington 
• Pen/Strep 
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• 2l beaker 
• 2l saline at 37C 
• 1.5ml tube floater 
• Razor blades 
• Petri dishes 
• 100 ul 2 N HCl 
• 100 ul 2 N NaOH 
 
Mice: 
1. anesthetize mouse  
2. pin mouse using 5-point method 
3. spray fur with 70% EtOH 
4. open abdominal cavity 
5. exsanguinate 
6. nick diaphragm to deflate lungs 
7. cut diaphragm along the bottom of the rib cage 
8. open thoracic cavity on left side 
9. cut under left clavicle to reveal trachea 
10. mop up blood around trachea with gauze 
11. cannulate trachea just below the larynx 
12. tie in cannula with 4-0 silk 
13. attach air-filled 1 ml syringe to cannula 
14. nick the right atrium 
15. perfuse with 10 ml 1X PBS 
a. left hand:  
i. forceps  
ii. grab heart along junction between ventricles 
iii. do not pull as this will occlude the pulmonary artery 
b. right hand: 
i. 26g needle attached to 10 ml syringe filled with 1X PBS 
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ii. Puncture right ventricle. Right ventricle wall is very thin.  
iii. You should feel a “pop” if you are in the right spot 
iv. You should be able to see the tip of the needle through the heart 
tissue 
v. Inject 10 ml PBS into ventricle  
vi. If all is well the lung will become white immediately 
vii. If the perfusion is going poorly try: 
1. Make sure the right atrium is cut and dark red blood is 
coming out.  
2. repositioning the needle (the ventricle is a rather small 
target and seems to collapse under these conditions). 
3. inflate the lungs with air via the tracheal cannula 
4. perfuse more slowly 
5. perfuse with another 10 ml PBS 
16. Lavage the lung with 4-1 ml 1XPBS/0.2 mM EGTA 
a. Attach a 1 ml syringe filled with PBS/EGTA to the tracheal cannula 
b. Instill PBS slowly over 5 seconds 
c. Withdraw PBS over 5 seconds 
d. Repeat 3 times 
17. Collect tissue 
a. remove heart lung block with cannula attached 
b. make sure the cannula is numbered 
c. immerse tissue in ice cold PBS in a 50 ml conical test tube  
d. store on ice 
 
Cell isolation procedure:  
18. Elastase solution: 
a. 3mls/animal (1X1 ml instillation and 4X0.5mls instillation) make about 
10% extra 
b. Ham’s F12 at 37C 
c. Figure out stock concentration of Elastase (U/ml) 
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d. Add the necessary volume of enzyme to get to 4U/ml 
e. Bring the pH of the solution up using NaOH  to 8.5 or 9 or until the 
solution starts clearing up. Make sure you don’t go over 10, because that 
might denature the enzyme. Once the solution is clear, add the necessary 
amount of HCl to bring the pH back down to 7.4. Filter through the 0.2um 
syringe filter.  
19. Pour saline into 2L beaker 
20. place float into beaker 
21. attach tissue to float by passing cannula flange through hole in float 
22. fill 1 ml syringe with 4 u/ml elastase 
23. instill 1 ml elastase into each lung 
24. incubate 5 minutes 
25. repeat 4 times with 0.5mls elastase 
26. remove digested tissue from float by pulling through hole 
27. place each lung in a separate bacterial grade Petri plate 
28. cut off lung tissue and place in a pile on a dry section of the Petri plate 
29. discard heart, thymus, and trachea in red bag 
30. drain/aspirate residual liquid (get tissue as try as possible) 
31. collect tissue in the “corner” of the plate 
32. mince tissue with scissors until about 2 mm2     
33. mince tissue with razor blade 
34. add 5 ml DNAse I to tissue 
35. incubate 5-10 minutes at 37°C in the incubator 
36. add  10mls cold HBSS and triturate tissue by pipetting  up and down 
37. transfer to cell strainer positioned in a 50 ml conical test tube 
38. rinse plate and tissue in strainer with 2X10 ml HBSS 
39. underlay cell suspension with 5ml FBS 
40. centrifuge 500g, 8 min, 4°C  
a. use the break to clean the hood 
41. pour off supernatant 
42. disperse cells by “racking” 
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43. resuspend cells in 1 ml RBC lysis buffer 
44. incubate 1.5 minutes  
b. time this with a watch 
c. a longer incubation will result in epithelial cell lysis 
45. add 10 ml HBSS+ to cells 
46. centrifuge 700g, 8 min, 4°C 
47. aspirate supernatant 
48. disperse cells by “racking” 
49. resuspend cells in 1ml cold HBSS+ 
50. count in trypan blue. I usually use a 1:10 dilution in HBSS+, 10ul cells and 10ul 
Trypan blue. Count 5 squares, average and multiply by 20X10*4. 
51. Use for further applications. 
52. Expected yield:  average 6X10*6 cells, or between 4X10*6 and 13X10*6 cells. 
 
 
 
A.2 CELLS SURFACE STAINING FOR FLOW CYTOMETRY 
Materials:   
• cells, HBSS+(HBSS 10mM HEPES 2%FBS), Antibodies, viability dye (7AAD or PI) 
Method: 
1. Resuspend cells at 10*6 cells in 100ul of HBSS+ 
2. Add the desired amount of antibody 
3. Incubate on ice in the dark for 30 min 
4. Add 1ml of HBSS+ 
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5. Spin down 500g  for 7min 
6. Remove supernatant by inverting the tube and placing it upside down on a piece of 
paper towel so that  most of the supernatant is absorbed 
7. Resuspend in 300ul HBSS+  
8. Add viability dye. I use 7AAD, 2ul per 100ul HBSS+ 
9. Read tubes. 
Notes: 
Blocking:  I usually do not use Fc Block. Most of the cells that have Fc receptors are in 
the CD45 CD31 positive fraction and I exclude those from the analysis anyway. I tried with or 
without block and I did not see much of a difference. I block when I do intracellular staining 
with unconjugated antibodies. 
Isotype controls:  I usually do them the first time I use a new antibody, and if they look 
clean, I do not use them again. They do not bring any information about the non-specific binding 
of the antibody used, they only tell us about the non-specific fraction of that particular Ig fraction 
of the serum.   
Always stain 10*6 cells in 100ul HBSS+. Scale up or down if needed (for sorts for 
example, where I usually stain about 10X10*6 cells). 
Always titrate antibodies. Pick the concentration that gives the best signal to noise ratio. 
Ideally, every time you change the LotNo of the antibody, even if it’s an antibody you’ve used 
before, you should do a titer run.  
For intracellular staining see protocol in Current protocols in immunology. It works well.  
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For Biotinylated antibodies, after the first incubation with the primary antibody, wash and 
incubate for 15- 30 min with SA. Remember to titrate SA and include a SA only control. Lung 
has a lot of endogenous biotin, thus keep the SA concentration to a minimum. 
Controls:  
1. Compensation controls: single color tubes. Be aware of the high autofluorescence of the 
airway epithelium. Make sure you compensate on populations of equal autofluorescence 
and adjust compensation values before analysis. For sorting experiments ALWAYS 
compensate manually. Always use biexponential display of the data to see events under 
the axis.  
2. FMO’s:  fluorescence minus one controls. Have samples that have all but one of the 
antibodies added (take out one antibody at a time). These controls allow the proper 
discrimination between the positive and negative populations.  
3. BrdU: always include cells isolated from a mouse that did not receive BrdU as control. It 
is the most valid control, much better than the Isotype and no primary antibody controls.  
4. Streptavidin only controls and No primary controls. When I use Zenon kits, I include 
Zenon complexes alone, without the primary antibody. In my experience, the kit is not 
cleaner than regular primary/secondary staining. 
 
 
A.3 NAPHTHALENE TREATMENT PROTOCOL 
Reagents 
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Naphthalene: Fisher Scientific N134-500; store at room temperature; use gloves and 
work in chemical fume hood when working with naphthalene 
Corn oil: Just buy Mazola corn oil.  Aliquot @ 25 mL in 50 mL conical tubes and store at 
-20 C (thaw on day of use) 
 
Naphthalene solution 
1. Estimate the overall volume that you need to deliver.  This is based on mouse mass.  
Assume about 35 grams for the average mouse (change if need for different mouse lines). 
A) 35 grams/mouse   X   # of mice in study   =   X grams of “mouse mass” 
B) Assume that you will deliver 10 μL of NA solution per gram of mouse mass.   
 
μL of solution needed = 
(g of mouse mass from 1A) (10 μL of NA solution / g mouse mass) 
 
Then, it’s actually best to add volume; say that you needed 4.5 mL; you should 
plan to make 5 or 6 mL, to allow for extra and loss during transfers. 
 
2. Estimating Naphthalene (solute) mass needed 
Notes on dose are elsewhere; say you are planning on 250 mg NA/kg of mouse mass.  
This means that you need to prepare a working solution that is 25 mg NA/mL.  This results from 
our assumed volume of delivery: 
 
10 μL      10,000 μL      10 mL 
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------------------------- = ---------------------------      =  ----------------------- 
1 gram mouse mass    1 Kg mouse mass                   1 Kg mouse mass 
 
 
         250 mg NA                     1 Kg mouse mass               25 mg mouse mass 
So:    ---------------------   X     -------------------------  =      ------------------------- 
         1 Kg mouse mass                 10 mL                                   mL 
 
 
So, (25 mg/mL) (Volume from 1B) = mass of NA needed 
 
3. USING GLOVES, weigh out naphthalene.  The best procedure here is to work with 
Naphthalene in a chemical fume hood.  However, most people do not have their analytical 
balance in their chemical fume hood.  The easiest way around this is to: A) Place a small beaker 
on the balance; place an empty 50 ml conical tube in the beaker; tare the balance B) take the tube 
to the hood and put in your best estimate of the amount of naphthalene needed; recap the tube C) 
bring the CLOSED tube back to the balance, place in the beaker, and weigh it.   Repeat until you 
have exactly enough naphthalene (which rarely happens) or you have more than enough.  You 
can easily compensate for having more than enough in the next step. 
4. A) Calculate amount of Mazola corn oil solvent needed.  Just set up a proportion to 
correct for the excess NA you probably have from step 3. 
  
 1 mL of solution               X mL 
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 --------------------   =       ---------------------------- 
 25 mg NA      mass actually weighed 
Solve for X. 
 
    B) You would think you would now just add the volume, X, to the tube with the 
naphthalene in it.  Unfortunately, corn oil is difficult to pipet in accurate volumes due to 
viscosity, and the fact that it sticks to the sides of the pipets, leaving a residue that would create 
large volumetric errors.  Instead, it is easier to add the necessary mass of corn oil.  Place the 
conical with the naphthalene on the balance, zero it, and pipet corn oil until the correct final mass 
is reached.  To calculate the mass needed, you need to know the approximate density of Mazola 
corn oil, which is 0.9185 g/mL. 
Calculate: 
(X from step 3) (0.9185 g/mL) = mass of corn oil needed. 
 
5. Cap tube, use tape or strong rubber bands to attach to vortexer, vortex on high for 20 
minutes or until NA is reasonable well dissolved, or at least a well-dispersed slurry. 
 
Preparation of syringes 
1. Obtain 1 mL syringes (“tuberculin” syringes).  Remove the normal 26 gauge needle; 
replace with 18G needle.   
2. Load working NA solution (a full 1 mL per syringe).  Carefully remove needle, and 
rigorously clean the end of the syringe; clean it until it squeaks, leaving no slippery 
residue!   
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3. Only then should the original 26G needle be replaced.  If there is a residue, when you are 
trying to inject, the needle will very likely just pop off, leaving a mess, and leaving you 
unsure how much NA was actually delivered to the animal; the animal would have to be 
removed from the study.  Cap
 
 needles; take to mouse colony. 
Injection 
1. Always inject before 10:00 am to take advantage of the daily minimum in mouse 
glutathione levels. 
2. Weigh animals to the nearest 0.1 gram.  A small, light plastic container on a portable top-
loading balance works best.  Bouncy mice are hard to weigh; some people use light 
anesthesia with halothane to get accurate weights.  RECORD animal’s weight.  Weight 
loss data is an invaluable method to make preliminary assessments of injury. 
3. Inject working NA solution at 10 μL/g of mouse body weight.   
4. Make sure that the injection is intraperitoneal and not subcutaneous.  If a bubble raises in 
the skin, it’s sc.  Do not nick the viscera, etc.  If you inject the bladder, the mouse will die 
almost instantly! 
 
Dose 
1. We have not done a formal study of all strains, but some information is available from 
GW Lawson et al., AJ Path 160(1):315-27, Jan 2002.   
2. Females are more sensitive than males. 
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3. For FVB/n: 275-300mg/kg results in extensive injury from the bronchi through the 
terminal bronchioles.  Some lethality is observed at 300 mg/kg.  At all doses the animals 
will exhibit ruffled fur at about 36 hours and will have reddened eyes at 48 hours. 
4. Large animals will require a larger dose to achieve the same level of injury due to 
partitioning of the naphthalene to the fat stores. 
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